

**MATERNAL AND PERINATAL OUTCOME IN PREGNANCY
FOLLOWING RECURRENT PREGNANCY LOSS**

*Dissertation submitted in partial
fulfillment of requirements for*

M.D. DEGREE BRANCH II

**OBSTETRICS AND GYNAECOLOGY
THANJAVUR MEDICAL COLLEGE
THANJAVUR**



**THE TAMIL NADU Dr. M.G.R. MEDICAL UNIVERSITY
CHENNAI**

MAY 2018

CERTIFICATE

This is to certify that the dissertation titled " **MATERNAL AND PERINATAL OUTCOME IN PREGNANCY FOLLOWING RECURRENT PREGNANCY LOSS** " is a bonafide work done by **Dr.B.MANOCHITHRA** in the department of Obstetrics and Gynaecology (ThanjavurMedical College) Thanjavur, in partial fulfillment of the university rules and regulations for award of MD degree in Obstetrics and Gynaecology under my guidance and supervision during the academic year 2015-2018

Prof.DR.JEYAKUMAR, M.S.,Mch.,
Dean,
ThanjavurMedical College,
Thanjavur.

Prof.DR. S. PRADEEBA, M.D.,OG,
Guide and Head of the dept,
Dept of obstetrics and gynaecology,
Thanjavur medical college,
Thanjavur.

Urkund Analysis Result

Analysed Document: INTRODUCTION.docx (D31328018)
Submitted: 10/15/2017 2:00:00 PM
Submitted By: manochithra89@gmail.com
Significance: 8 %

Sources included in the report:

THESIS 1.docx (D30657802)
HUMAIRA THESIS FINAL 2 new.docx (D31067006)
<https://www.dovepress.com/recurrent-pregnancy-loss-current-perspectives-peer-reviewed-fulltext-article-IJWH>

Instances where selected sources appear:

33

DECLARATION

I solemnly declare that this dissertation titled "MATERNAL AND PERINATAL OUTCOME IN PREGNANCY FOLLOWING RECURRENT PREGNANCY LOSS" was done by me at department of Obstetrics and Gynaecology, Thanjavur Medical College during the year 2015 - 2018 under the guidance and supervision of **Prof.DR.S.PRADEEBA MD OG..**, This dissertation is submitted to The Tamil Nadu Dr.M.G.R. Medical University towards the partial fulfillment of requirements for the award of M.D. Degree in Obstetrics and Gynaecology (Branch -II)

Signature of the Candidate

**Dr.B.MANOCHITHRA
MD Post Graduate Student
Department of Obstetrics and Gynaecology
Thanjavur Medical College, Thanjavur.**

**GUIDE: Prof. DR. S. PRADEEBA, M.D.,OG,
HOD, Dept of obstetrics and gynaecology
Thanjavur medical college,
Thanjavur.**

Place:

Date:

ACKNOWLEDGEMENT

I gratefully acknowledge and sincerely thank **Prof.Dr.JEYAKUMAR.,M.S.,Mch., The Dean**,Thanjavur Medical College and Hospital, Thanjavur for permitting me to conduct the study and use the facilities of the institution for my study.

I am grateful to the Head of the department, **Prof.Dr.S.PRADEEBA MD.,OG**, department of Obstetrics and Gynaecology, Thanjavur medical college, Thanjavur for being my guide and helping me all through the study.

I sincerely thank **Prof.Dr.R.RAJARAJESWARI MD., DGO.** helping me all through the study. .

I am bound by ties of gratitude to my respected teacher **DR.ANJUPADMASEKAR M.D.**, for her valuable guidance in conducting this study.

I wish to express my sincere thanks to all the Assistant Professors of our department for their support during the study.

I thank the secretary and chairman of Institution Ethical Committee, Thanjavur medical college, Thanjavur.

I also thank **DR. MAHESHWARAN M.D.**, who helped me a lot in doing statistics of my study.

I would be failing in my duty if I don't place my sincere thanks to those patients who were the subjects of my study . Above all I thank God Almighty for His immense blessings.

ABBREVIATIONS

RPL : Recurrent pregnancy loss

hCG : Human chorionic gonadotrophin

PGD : Preimplantation Genetic diagnosis

PGT : Preimplantation Genetic testing

VEGF: Vasculo Endothelial Growth factors

APLA: Antiphospholipid antibody syndrome

LH : Leutinizing Hormone

PCOS: Poly cystic ovarian syndrome

TRH : Thyroxine releasing hormone

PROM: Premature Rupture of membranes

CS : Caeserean Section

IUGR: Intrauterine growth restriction

IUD: Intrauterine fetal death

APH: Antepartum Haemorrhage

CPD: Cephalo Pelvic disproportion

GHT: Gestational Hypertension

CTG: Cardio tocography

AP Eclampsia: Antepartum eclampsia

GDM: Gestational Diabetes Mellitus

NICU: Neonatal intensive Care unit

TABLE OF CONTENTS

SL.NO	TITLE	PAGE NO
1.	Introduction	1
2.	Review of literature	7
3.	Aims and objectives	47
4.	Materials and Methods	48
5.	Observation and Results	49
6.	Statistical methods	70
7.	Discussion	71
8.	Summary	83
9.	Conclusion	84
10.	Bibliography	85
11.	Annexures <ul style="list-style-type: none">• Proforma• Consent form• Master Chart	

INTRODUCTION

Successful reproductive outcome in pregnancy is the goal and motivation of women with a history of recurrent pregnancy loss. Recurrent pregnancy loss (RPL) has a controversial definition.

Recurrent pregnancy loss is a heterogeneous reproductive problem, with multiple aetiologies and contributing factors. As such, evaluating and treating women with this condition is a complex task, and research in the field is no less daunting.

The definition of recurrent pregnancy loss is debated, ranging from two clinical miscarriages, not necessarily consecutive, according to the American Society for Reproductive Medicine (ASRM) (ASRM Practice Committee, 2013) and a joint International Committee for Monitoring Assisted Reproductive Technology and World Health Organization glossary (Zegers-Hochschild et al., 2009), to three consecutive pregnancy losses (not necessarily intrauterine) as defined by both the European Society for Human Reproduction and Embryology (Jauniaux et al., 2006) and the Royal College of Obstetricians and Gynaecologists (RCOG Green Top Guideline, 2011).^{1,2,3,4}

Consensus Statement from the ESHRE Special Interest Group, Early Pregnancy (2014) recommend the term recurrent pregnancy loss be used to describe repeated pregnancy demise, and the term recurrent miscarriage be used when all pregnancy losses have been confirmed as intrauterine miscarriages, by ultrasound or histology.⁵

Under normal, non-neoplastic conditions, human chorionic gonadotrophin (hCG) is exclusively produced by the syncytiotrophoblast. It follows logically that a pregnancy loss is the spontaneous demise of a pregnancy, which has been confirmed by at least two positive b-hCGs in the serum or urine (kolte et al, 2014).⁶ The general availability of high-resolution transvaginal ultrasound in developed countries, combined with sensitive urine and serum b-hCG measurements, has revolutionized the diagnosis of pregnancy in very early gestation. Any pregnancy loss, which has not been confirmed ultrasonically or histologically, should be classified as a non-visualized pregnancy loss, irrespective of the time passed since the last menstrual period or clinical presentation. If the pregnancy has been diagnosed only by either serum or urine b-hCG, and the serial results decrease to negative, the pregnancy loss should be termed a biochemical pregnancy loss.

In the latest ASRM Practice Committee Opinion on the definition of recurrent pregnancy loss, a pregnancy is defined ‘as a clinical pregnancy documented by ultrasonography or histopathologic examination’ (ASRM Practice Committee, 2013).¹ They suggest a clinical evaluation should proceed following two first-trimester pregnancy losses, and, ideally, the threshold of three or more losses should be used for epidemiological studies.

As the diagnosis of RPL is based on self-reported losses which occurred in the past, it may not be accurate, as the women in the general population do not have their β hCG routinely measured and, consequently, their biochemical loss rate is underestimated. In contrast, women with RPL often have closer biochemical monitoring, which is less likely to be missed. The proportion of women with unexplained RPL (approximately one of three) may have environmental risk factors or endogenous pathologies not detected by current routine investigations.

In 1930s and 1940s, Malpas and Eastman suggested that the proportion to pregnancy losses in next pregnancy after three consecutive losses was as high as 73 -84%.⁷ Years later, it has been demonstrated in several clinical studies that the risk of miscarriage is lower than what has been predicted.

Clinically recognised pregnancy loss is common occurring in approximately 15-25% of pregnancies. Majority of sporadic losses before 10 weeks of gestation results from random numeric chromosome errors, specifically, trisomy, monosomy and polypoidy. In contrast, Recurrent Pregnancy loss is a distinct disorder defined by two or more failed clinical pregnancies. It is estimated that fewer than 5 % of women will experience two consecutive pregnancy miscarriages and only 1% experience 3 or more (ASRM practice committee, 2013).¹

In the recent era, investigation and treatment is considered in couples with two consecutive spontaneous miscarriages, documented by ultrasound or histopathological examination (Leon Speroff et al).⁸

Evaluation is indicated when any of the following are present

1. Embryonic heart activity observed before any earlier pregnancy loss
2. Normal karyotype of the products of conception obtained from an earlier loss
3. Female partner over 35 years of age
4. Women with previous history of infertility

The risk of recurrent pregnancy loss in young women:

Table 1: women who have had atleast one live born infant⁹

Number of Prior miscarriages	% risk of miscarriages in next pregnancies
0	12%
1	24%
2	26%
3	32%
4	26%
5	53%

Future pregnancy outcome is significantly affected by previous reproductive history. Risk of miscarriage is found to be reduced in women who had prior live births when compared to women whose prior pregnancy has ended in miscarriage.

Table 2: Women who have not had atleast one live born infant¹⁰

Number of prior miscarriages	% risk of miscarriage in next pregnancies
2	24%
3	30%
4	40-50%

The prognosis for successful pregnancy depends both on the underlying cause and the number of previous losses. The chance of a viable birth even after four pregnancy losses is as high as 60%.

Prognosis for a viable birth After

One spontaneous loss :76%

Two spontaneous loss :70%

Three spontaneous loss: 65%

Four spontaneous loss: 60%

When a causative factor is identified, specific treatment can help in improving the prognosis for a successful pregnancy. The prognosis for a successful pregnancy outcome can be enhanced by determining the etiology, early identification of complications and being cautious of adverse maternal and perinatal outcomes.

REVIEW OF LITERATURE

Recurrent Pregnancy loss, affecting 1-2% of women of reproductive age seeking pregnancy, has been a clinical quagmire and a formidable challenge for the treating physician. There are many areas of controversy in the definition, aetiology, investigations and treatment of RPL. There is no identifiable cause in about 40-60% of these patients, in which case the condition is classified as idiopathic or unexplained RPL. The RPL investigations are extensive and should be undertaken in dedicated, specialized, well-equipped clinics/centres where services are provided by trained specialists. The challenges faced by the treating physician are even more overwhelming regarding the decision of what should be the most appropriate therapy offered to patients with RPL.

Patients presenting with RPL have experienced psychological trauma as they face the uncertainty of the outcome of the next pregnancy, and a variety of psychological and psychiatric disorders including anxiety, depression, posttraumatic stress disorders, and obsessive-compulsive disorders develop in these patients after RPL.¹¹

EPIDEMIOLOGY OF PREGNANCY LOSS

Spontaneous pregnancy loss can be physically and emotionally taxing for couples, especially when faced with recurrent losses. It is a surprisingly common occurrence. Whereas approximately 15% of all clinically recognized pregnancies result in spontaneous loss, there are many more pregnancies that fail prior to being clinically recognized. Only 30% of all conceptions result in a live birth (Macklon NS et al, 2002).¹² Based on the incidence of sporadic pregnancy loss, the incidence of recurrent pregnancy loss should be approximately 1 in 300 pregnancies.¹³ However, epidemiologic studies have revealed that 1% to 2% of women experience recurrent pregnancy loss (Stephensen MD , 1996).¹⁴

Although no reliable published data have estimated the probability of finding an etiology for RPL in a population with 2 versus 3 or more miscarriages, the best available data suggest that the risk of miscarriage in subsequent pregnancies is 30% after 2 losses, compared with 33% after 3 losses among patients without a history of a live birth (ACOG practice bulletin no.24).¹⁵

Nearly all chromosomally abnormal conceptions get aborted spontaneously before 10 weeks of gestation, and 90% of those with a normal karyotype continue.¹⁶ Spontaneous abortion can also be viewed as a natural selection process for quality control by deleting chromosomally abnormal fetuses. Nearly about 30 - 60% of all conceptions will spontaneously get aborted within first 12 weeks of gestation; out of which half of the losses go unnoticed and this loss occurs even before a first missed menses.

AGE AND MISCARRIAGE

In recent decades, an increase in mean maternal age at childbirth in most high-resourced countries has been observed evidently. Advanced maternal age which is considered above 35years is being strongly associated with several adverse maternal and perinatal outcomes.¹⁷ Advanced maternal age is considered as a major influencing factor for RPL due to the formation of chromosomally abnormal conceptions.¹⁸ As age advances, there is increase in the incidence of mitotic segregation errors, rapid increase on number of aneuploid oocyte. Women with evidence of low ovarian reserve have an exceptionally higher rate of miscarriage, regardless of age.¹⁹ Hence advancing maternal age adds up to the risk of

miscarriage in women with history of previous pregnancy losses. If both occult and recognized losses are being considered, total pregnancy loss in women above 40 years of age may exceed 75%.

Clifford K et al (1997), showed a 25% rate of miscarriages in women less than 30 years, increasing to 52% in a group of women older than 40 years.²⁰ They also concluded that increasing maternal age and number of previous miscarriages both had a negative effect on pregnancy outcome. To the contrary, a history of a live birth did not influence the outcome of the next pregnancy.

GESTATIONAL AGE AT THE TIME OF MISCARRIAGE

In a population of women with RPL, losses are likely to occur again at gestational ages similar to those previously documented.²¹ These observations suggest the possibility of specific, but yet undiscovered, causes of loss that influence the viability of pregnancy at precise gestational ages. The chromosomal abnormalities are present in more than 90% of pre embryonic-aborted tissues, compared with only 6 to 12% of losses after 20 weeks gestation. The women with mid-trimester pregnancy loss represent a heterogeneous group with widely varying presentations

and origins. Fetal loss may have more than one cause, and the presence of dual or even triple pathologies increases the risk of a further late-term miscarriage or preterm delivery.²² Mid-trimester pregnancy loss can be attributed to Antiphospholipid Syndrome and anatomic cervical incompetence.

PROGNOSTIC VALUE OF TRANSVAGINAL ULTRASOUND OBSERVATIONS


The risk of miscarriage decreases as the duration of pregnancy advances. The risk of pregnancy loss falls progressively after appearance of gestational sac (12%), yolk sac (8%), as crown rump length increases, (greater than 5mm – 7%, 6 – 10mm – 3%, more than 10 mm – less than 1%).The important ultrasound findings in pregnancies that subsequently resulted in fetal loss, compared to those resulting in live births, were a small gestational sac diameter and fetal bradycardia.

Appearance of embryonic cardiac activity by approximately 6 weeks is another important developmental mile stone and good prognostic indicator. In both normal and infertile asymptomatic young women, the

appearance of embryonic heart activity decreases with the risk of pregnancy losses from 12% - 15% to 3 – 5%.²³

ETIOLOGY OF RECURRENT PREGNANCY LOSS

- 1) Genetic factors : 3.5 – 5 %
- 2) Anatomical factors : 12 -16 %
- 3) Endocrine factors : 17 – 20 %
- 4) Infectious factors : 0.5 – 5 %
- 5) Immunologic factors : 20 -50 %
- 6) Thrombotic factors
- 7) Others: 10 % (environmental, placental abnormalities, male factors, medical illness, altered uterine receptivity, exercise)



GENETIC FACTORS

A considerable proportion of pregnancy losses are due to genetic abnormalities in the embryo. Many of them are due to de novo non disjunctional events but balanced parental translocations are responsible for small yet significant proportion of genetic abnormalities in couples with recurrent pregnancy loss. In recent era, molecular genetic technology provide ample amount of genetic information about other genetic causes and risk factors for recurrent pregnancy loss.

Large number of abortuses so far cultured and karyotyped suggest that approximately 50 % of all first trimester pregnancy losses, 30% of second trimester abortuses, and 3 % of still births are chromosomally abnormal.²⁴

Chromosomal abnormalities:

90% - numerical (aneuploidy, polyploidy)

10% - structural abnormality (translocation , inversion and mosaicism)

Numerical chromosomal abnormalities:

The remarkable inefficiency of human reproduction is largely the result of spontaneous fetal aneuploidy. Nearly 50 – 70 % of sporadic spontaneous

abortions have some form of cytogenetic abnormality, the most common abnormalities being autosomal trisomies (60%), monosomy X (20%) and polypoidy (20%) (Silver and branch, 2007).²⁵ Most of these defects are due to random errors in germ cell development which equally affects pregnancies regardless of history of RPL.

Typically, numerical aneuploidy results from meiotic non disjunction in the germ cells in couples with normal karyotypes, and the recurrence of a particular abnormality in future pregnancies is rare in patients with RPL and in the general population (Warren and silver, 2008 ; suzumori and Sugiura-Ogasawara, 2010).^{26,27} So most of the losses in RPL are the result of random, non recurring events and hence the prognosis for subsequent of pregnancies in RPL couples is better after an aneuploid miscarriage than after an euploid miscarriage (Warburton et al, 1987; Ogasawara et al 2000; Carp et al , 2001).^{28,29,30}

Autosomal trisomy are the most common usually involving chromosome 13 – 16, 21 or 22, followed by monosomy X (45 X),42,44,45,21. The likelihood of euploid abortus increases with the number of previous miscarriages and after a previous abortion having a normal karyotype.

Structural chromosomal abnormalities:

Structural chromosomal abnormalities are an unequivocal explanation for repetitive abortions. The most common structural rearrangement encountered is a translocation, found in about 5% of couples experiencing repeated losses. Individuals with balanced translocations are phenotypically normal, but their offspring (abortuses or abnormal live-born infants) may show chromosomal duplications or deficiencies as a result of normal meiotic segregation. Among couples with repetitive abortions, about 60% of translocations are reciprocal and 40% robertsonian. Females are about twice as likely as males to show a balanced translocation.

Inversions

Inversions are uncommon parental chromosomal rearrangements, but responsible for repetitive pregnancy losses analogous to translocations. In inversions, the order of genes is reversed. Individuals heterozygous for an inversion should be normal if their genes are truly just rearranged. However, individuals with inversions suffer untoward reproductive consequences as result of normal meiotic phenomena. Pericentric inversions are present in perhaps 0.1% of women and 0.1% of men

experiencing repeated spontaneous abortions. Paracentric inversions are even rarer.

In the evaluation of RPL, Parents should undergo peripheral karyotyping in order to detect any balanced structural chromosomal abnormalities. Balanced reciprocal translocations and robertsonian translocations are observed in about 2-5% of couples with recurrent miscarriage. Genetic counselling is important when a structural genetic abnormality is detected. The likelihood of subsequent healthy live birth depends on the chromosome(s) involved and the type of rearrangement. When one of the partners has a structural genetic abnormality, preimplantation genetic testing (PGT), amniocentesis, or chorionic villus sampling are options to detect the genetic abnormality in the offspring. Treatment options include preimplantation genetic diagnosis (PGD) for specific translocations , with transfer of the unaffected embryos, or the use of donor gametes.

Karyotyping data are likely to underestimate the prevalence of chromosomal abnormalities due to unrecognized maternal cell contamination; normal euploid cells are less likely to fail culture than abnormal cell lines.³¹ Some genetic abnormality cannot be detected using standard cytogenetic techniques like isolated gonadal / germ line mosaicism/ single gene defects.

Analysis using newer techniques not dependent on cell culture (FISH – fluorescence in situ hybridization, CGH – comparative genomic hybridization) suggest that the true incidence of chromosomal abnormalities in miscarried early pregnancies is closer to 75%.

ANATOMIC FACTORS

CONGENITAL UTERINE MALFORMATIONS

Congenital anomalies are found in 8.4%–12.6% of women with RPL, which is seven to eight times higher than the general population.(Jaslow, 2014; Grimbizis GF, 2001).^{32,33}

Congenital abnormalities are the consequence of an abnormal development of the Müllerian ducts and include septate, bicornuate, unicornuate, didelphic, and arcuate uteri. They are reportedly found in up to 10% of women with RPL (Jaslow CR, 2014).³²

Septate uterus is the most common uterine developmental anomaly accounting for 80-90% in both women with recurrent miscarriage (3.5% prevalence) and in general population. Miscarriage rate associated with septate uteri is 65 %.

Hysteroscopic septoplasty dramatically improved post operative pregnancy outcomes. (80% term, 5% preterm, 15% miscarriage). Arcuate uteri are a normal variant. Residual septal defect less than 1cm has no adverse effect on pregnancy.

A septate uterus leads to poor reproductive outcome:

1. Poor septum vascularization leading to poor decidualization and placentation (Dabirashrafi 1995, Kupesic 1998, Kupesic 2001).^{34,35,36}
2. Increased amount of muscle tissue in the septum can cause miscarriage by uncoordinated contractility
3. Reduced length of unaffected uterine cavity
4. Local defect of VEGF receptors (Raga Fertil Steril 2009).³⁷

Canalization defects appear to reduce the chance of clinical pregnancy and increase the chance of miscarriage and preterm delivery. These are more profound in cases of septate uteri. Unification defects do not reduce fertility but some defects, in particular bicornuate uteri, are associated with aberrant outcomes throughout the course of pregnancy. Cases of arcuate uteri, often considered an incidental benign finding, are specifically associated with poor outcomes in late pregnancy, i.e. second-trimester miscarriage.

There is a lack of randomized controlled trials (RCTs) concerning the impact of uterine metroplasty on reproductive outcomes in women with congenital uterine anomalies and RPL. Septate uterus is the most common type and has more chance of spontaneous abortion(Grimbizis GF et al, 2001).³³ There is evidence to suggest improved pregnancy rates following metroplasty (Valle RF et al ,2013) and it is highly recommended to do metroplasty in women with RPL having septate uterus.³⁸

The prevalence of arcuate uteri is the same as in general population, and their effect on reproductive outcome remains controversial (Grimbizis GF, 2001).³³ Therefore, arcuate metroplasty is not recommended in women with RPL (practice committee ASRM, 2012; Jaslow ; Valle).^{1,32,38} The other congenital abnormalities are more commonly associated with third trimester pregnancy loss and preterm birth, and the decision to treat or not is more complex (Grimbizis GF).³³

Metroplasty is not recommended for unicornuate uteri, is highly controversial for didelphys, and is only recommended as a last resort for bicornuate uteri (Alborzi S et al, 2009; Brucker SY, 2011).^{39,40} Finally, it should be noted that for women with RPL secondary to irreversible uterine anatomic defects, the use of a gestational carrier is a viable option.

DES EXPOSURE

Uterine anomaly was found in almost 70% of women exposed to DES which is rare nowadays . The common uterine abnormality is T shaped uterus, hypoplastic uterus, irregular intrauterine filling, constriction rings. As the women who have been exposed are beyond their reproductive age, women encountered with such abnormality is rare at present. The risk of spontaneous abortion is 24% and risk of ectopic pregnancy is increased by 9%.

UTERINE LEIOMYOMA

Some research has linked the presence of uterine fibroids with recurrent miscarriage in women, but the data thus far had been inconclusive. They impede embryonic implantation and causes poor regional blood flow. The expression of *HOX10*, a gene that controls differentiation and is involved in implantation, is found to be low in uterus with fibroids.

Hysteroscopic Myomectomy should be considered in cases of submucosal fibroids or any type fibroids larger than 5 cm. Resection has been shown to significantly improve live birth rates from 57% to 93%. Saravelos et al,2011 found that women with fibroids distorting the

uterine cavity had a total miscarriage rate of 76.7 percent and a live birth rate of 23.3 percent.⁴¹ Women with cavity-distorting fibroids also had a higher mid-trimester miscarriage rate (21.7 percent) than the group of women with unexplained recurrent miscarriages (8 percent). They found that women who had cavity-distorting fibroids and underwent hysteroscopic myomectomy had significantly improved outcomes, with a significant drop in the mid-trimester miscarriage rate and a live birth rate increasing from 23.3 % to 52 %.

INTRAUTERINE ADHESIONS

Decreased functional intrauterine volume, endometrial fibrosis and inflammation predispose to placental insufficiency. Pregnancy outcomes are generally poor. 40 – 80 % results in spontaneous miscarriage and 25 % ends in preterm delivery. The prognosis generally correlates with the severity of the disease. Hysteroscopic adhesiolysis dramatically improves the pregnancy outcome.

CERVICAL INCOMPETENCE

The diagnosis is based on a history of late second trimester miscarriage

characterized by painless cervical dilatation followed by ballooning of membranes and ultimately resulting in expulsion of fetus. Efficient treatment helps in preventing future miscarriage.

IMMUNOLOGICAL PHENOMENON

Pregnancy is a immunotolerance state. A subset of CD4 cells describe CD25 on their cell surface. These CD4, CD25 cells are called Regulatory T Lymphocytes (T reg cells). T reg cells when activated by autoantigens can suppress activated inflammatory cells.

Cellular Immune Mechanisms

Decidual NK cells comprises 70-80% of the total endometrial population at the implantation site. Human reproductive tract is populated by TCR $\gamma\delta$ + they are increased in early pregnancy; their functions are direct, non – MHC registered recognition of antigens within tissues. Suppressor macrophages helps in pregnancy maintenance. They help in promotion of anti – inflammatory effect. T reg cells suppress maternal responses to self and to the fetus.

Antigen Presentation at the Maternal Fetal Interface

Implanting trophoblastic allograft causes down regulation of its expression of the MHC – encoded transplantation antigens and avoid recognition as non – self. Current theory, in placental trophoblast MHC class I and II molecules are not expressed.⁴²

Extravillous trophoblast express classical MHC class I HLA – C and non – classical HLA – E and G products. They are characterized by their invasive potential deep into the maternal decidua, an activity essential for proper placental development. Aberrant expression of class II MHC; over expression of class I MHC leads to cytotoxic Tcell attack, could enhance abortion. MHC II genotypes appear to affect susceptibility to a variety of diseases, like diabetes and other auto immune diseases and adverse pregnancy outcome.

Regulation of maternal decidual cells

Regulatory mechanisms include

- i) Alterations in T- helper cell phenotypes
- ii) Reproductive hormones and immunosuppression
- iii) Tryptophan metabolism

CDT4 cells are divided into TH1 responses and TH2 responses. TH1 cells are associated with inflammation. They are harmful to the implanting embryo. TH2 cells are associated with IL – 4,5,6,10 and antibody production; they are important for pregnancy maintenance.⁴³ The dysregulation of their T-helper cellular immune response accounts for about 60-80%. Leukemia inhibitory factor is absolutely essential for pregnancy maintenance.

Humoral Immune Response

Patients with recurrent pregnancy loss display altered humoral responses to endometrial and trophoblast antigens; Historically these IgG and IgM antibodies (cardiolipin and phosphatidylserine) are thought to be directed against negatively charged phospholipids. More recently the high titre of antibodies directed against a protein cofactor, called $\beta 2$ glycoprotein I alone is sufficient for diagnosis.

LABORATORY ASSESSMENT (SAPPORO CRITERIA).⁴⁴

Antiphospholipid antibody syndrome requires presence of at least 1 clinical and 1 laboratory Criterion

- Clinical

1. One or more confirmed episodes of vascular thrombosis (venous, arterial, or small vessel).

2. Pregnancy morbidity

Pregnancy complications including

- ✓ 1 or more fetal deaths at greater than 10 weeks of gestation of a morphologically normal fetus.
- ✓ One or more premature birth of a normal neonate before 34th week because of pre eclampsia, or placental insufficiency .
- ✓ 3 or more consecutive pregnancy losses at less than 10 weeks of gestation.

- Laboratory (repeated at least 2 times, more than 12 weeks apart)

- ✓ Positive plasma levels of the anticardiolipin antibodies (IgG Or IgM) at medium to high levels
- ✓ Positive plasma levels of the lupus anticoagulant
- ✓ Anti β_2 – glycoprotein 1 antibody of IgG or IgM isotype in 99th percentile titre.

The incidence of APLAs in patients with RPL is between 3-5%; Less favourable pregnancy outcome was noted among patients with known

Systemic Lupus Erythematosus. Anti-thrombotic molecule (annexin V) is reduced within the placental villi resulting in atherosclerosis in decidual spiral arteries.

THROMBOPHILIAS

Abnormal placental vascularisation and inappropriate placental thrombosis would relate these thrombophilic states to pregnancy loss. The incidence of inherited thrombophilic mutations in Caucasians – 15%;

The most common are

- I) Factor V leiden – 5%
- II) Prothrombin promoter region mutation – 2-3%
- III) Mutation in gene MTHFR – 11-15% .They are associated with mild thrombotic risks.

Thrombophilic gene defects

The genetic defects involved in the ever-expanding group of inherited thrombophilias are perhaps the best studied single gene mutations with reference to RPL. Among these, the majority of reports have addressed factor V Leiden, prothrombin gene promoter mutations, activated protein C resistance, and mutations in methylenetetrahydrofolate reductase,

plasminogen activator inhibitor, thrombomodulin, and annexin A5 genes. Unlike trinucleotide expansion disorders and immune-related single gene mutations, the gene mutations causing several of the inherited thrombophilias are seen in relatively high prevalence in select populations. The data linking these defects to RPL, however, are conflicting. Mutations in factor V Leiden, the most common genetic cause of thrombosis, have a twofold higher prevalence in women experiencing repeated miscarriages compared with controls.^{45,46,47,48,49,50} Mutations in the gene encoding Annexin A5, a protein that acts as an anticoagulant in placenta villi, have also been associated with a twofold increase in RPL risk.⁵¹ Other cohort studies, however, have failed to confirm an association between RPL and inherited thrombophilias such as factor V Leiden and prothrombin promoter gene mutations and carriers and noncarriers of annexin A5 mutations have similar live birth rates, limiting the clinical significance of this particular mutation.^{45,52} In fact, there are data showing that when stratified for gestational age at the time of fetal demise, maternal carriage of the FVL mutation protects against pregnancy loss occurring before 10 wk of gestation.⁵³ This finding aligns with earlier data showing increased implantation rates in carriers of FVL who become pregnant through in vitro fertilization.⁵⁴ Together these studies support the concept

that FVL increases implantation of compromised embryos that would not typically implant and are ultimately lost.

Despite the growing evidence that thrombophilias caused by single gene defects may be associated with adverse pregnancy outcomes, the absolute risk of adverse outcomes remains low. Thus, current recommendations do not support universal screening for inherited thrombophilias in women with a history of pregnancy loss.^{55,56,57} Both the specific thrombophilia and the type of pregnancy loss (isolated vs. recurrent; early vs. late) contribute to the vast spectrum of documented associations and the underlying pathophysiologic mechanisms used to support these associations.⁵⁸

Despite the present recommendations, however, many practitioners will screen for prevalent inherited thrombophilias (factor V Leiden, prothrombin gene mutations and methylenetetrahydrofolate reductase in Caucasian patients; protein C, protein S and antithrombin deficiencies in some patients of eastern Asian descent) in RPL patients who have a first-degree relative with a known or suspected thrombophilia or who report a personal history of venous thromboembolism.¹

That said, data supporting treatment of a diagnosed gene defect associated with an inherited thrombophilia in the absence of a personal thrombotic history are weak. Although observational studies have shown a decrease in pregnancy complications in women with the Factor V Leiden mutation or mutation in the prothrombin promoter region that are prophylactically treated with low molecular weight heparin, there is a lack of randomized control studies that confirm these same findings.⁵⁹

Recently, two randomized controlled trials investigated the empiric use of aspirin alone or a combination of aspirin with low molecular weight heparin in women with RPL and found no improvement in live birth rate when compared with placebo.^{60,61} Based on current evidence, therefore, the empiric use of antithrombotic agents in women with unexplained RPL is not recommended.^{4,61}

More randomized placebo-control trials are needed to show both a mechanistic association between inherited thrombophilias and RPL and successful treatment options to improve live birth rates in couples suffering from recurrent miscarriage.

The current studies on maternal-fetal interface immunity revealed that both second-trimester abortion and spontaneous preterm birth, similar to those of Preeclampsia and Fetal growth restriction, suffered from abnormal immune cell function and cell number, leading to disorders of maternal-fetal tolerance and uterine spiral artery reconstructions (A.Ekin et al, 2015).⁶² Recent reports have shown that about 50-65% of women with unexplained spontaneous abortion have at least one inherited or acquired prethrombotic state (PTS) [G.Mitic et al, 2011].⁶³ In PTS, FVL mutation raises the risk of early miscarriages and early intrauterine fetal deaths [M.A.Rodger et al,2011].⁶⁴ Meta-analysis has shown that late spontaneous abortion is closely related to factors V and II (prothrombin) mutations and to the lack of protein S induced congenital thrombosis [G.Kovalevsky et al ,2004].⁶⁵

Clinically, patients with RSA are not recommended for routine hereditary thrombosis test, in that mutations of factors V and II (prothrombin) in domestic Han population are rare. Therefore, tests of FVL, coagulation factor VIII, antithrombin, and protein C are only recommended for patients with a thrombosis family history and who suffered from unexplained FRSA.

INFECTIOUS CAUSES

Spontaneous miscarriage has found to be associated with Chlamydia trachomatis, Ureaplasma urealyticum or Mycoplasma hominis infection. Toxoplasma gondii, Listeria monocytogenes, Campylobacter species, herpes virus, and cytomegalovirus has also been implicated. Many studies has been conducted to correlate the association between miscarriage risk and Bacterial vaginosis. There is 5 fold increased risk of pregnancy loss before 20 weeks of gestation when Bacterial Vaginosis was diagnosed at the first prenatal visit before 14weeks.⁶⁶

Chronic subclinical endometritis in women with symptomatic lower genital tract infection explains association between infection and miscarriage. Chronic endometritis (CE) is defined as chronic inflammation of the endometrial lining, and some studies have shown an increased prevalence in women with RPL (10%–27%).^{67,68,69} Endometrial receptivity is thought to be impaired by the stromal infiltration of plasma cells, as well as altered expressions of genes involved in implantation, leading to RPL but also infertility and recurrent implantation failure following in vitro fertilization (IVF).⁶⁹

Several methods have been used to confirm the diagnosis of CE, but the gold standard is identification of plasma cells in the endometrial stroma, using immunohistochemistry stains for syndecan-1 (CD138), a marker of plasma cells.⁶⁹ The etiology is most likely infectious, and many treatment regimens with antibiotics have been proposed, the most widely used being doxycycline (200 mg per day for 14 days), with some studies reporting favorable outcomes following treatment.^{67,68,69} However, no randomized trials have been published to date, and controversies remain concerning the impact of CE on reproductive outcome, the patient population to screen, the treatment regimen, and need for a biopsy to confirm resolution.

Given the lack of conclusive evidence, several international societies do not include screening for CE in their recommendations.^{1,4} Several other infections have been investigated as potential causes of early miscarriage. There is some evidence that bacterial vaginosis (*Mycoplasma hominis*, *Ureaplasma urealyticum*), brucellosis, syphilis, cytomegalovirus, dengue fever, human immunodeficiency virus, rubella, and malaria are more frequently found in women with spontaneous miscarriage.⁷⁰ However, no causal link has been established, and it is not recommended to test or empirically treat asymptomatic women with RPL.

ENVIRONMENTAL FACTORS

SMOKING: Smokers who consume 10 cigarettes / day has adverse pregnancy outcome. The anti metabolite composition of cigarette like nicotine, carbondioxide and cyanide may predispose to placental insufficiency .

ALCOHOL: Consumption exceeding two drinks / day increases the risk. It adds to the additive risk with smoking.

CAFFEINE: Heavy caffeine consumption more than 300 mg / day, equivalent to 3 cups / day - 2 fold increased risk of spontaneous miscarriage.

OBESITY: A body mass index equal to or greater than 25 is associated with greater risk of miscarriage.⁷¹

Others

Anaesthetic gases (Perchlorethylene)

- ✓ Exposure to heavy metals (Mercury,Lead)
- ✓ Isotretinoin (Accutane)
- ✓ Painters and factory workers.

Male factors

Sperm samples from recurrent pregnancy loss couples have an increase in their sperm DNA fragmentation.^{72,73,74} Meta-analysis showed a significant increase in miscarriage in patients with high DNA damage compared with those with low DNA damage.⁷⁵ The associating sperm quality with recurrent pregnancy loss emphasizes the importance of evaluating male factor by tests. Several different tests are available, but no consensus has yet been reached as to which tests are most predictive.

Among terminal uridine nick-end labeling assay (TUNEL), sperm chromatin structure assay (SCSA), sperm chromatin dispersion (SCD), and alkaline Comet assays, the alkaline COMET assay showed better prediction for male infertility.⁷⁶ A chromosomal abnormality was found in 15.2% men with azoospermia and in 2.3% nonazoospermic men.

Male factors abnormality is a significant cause for recurrent pregnancy loss after assisted conception. The number of azoospermic men who needs to be screened to prevent one miscarriage is 80–88 and the number need to screen is 315–347 in the nonazoospermic group.⁷⁷ Although there is some evidence of association between DNA defragmentation and

recurrent miscarriage, well-designed prospective studies are needed before using these tests in clinical practice.⁷⁸ Routine testing for sperm ploidy (e.g. fluorescence *in situ* hybridization [FISH]) or DNA fragmentation is not recommended.

UNEXPLAINED RECURRENT PREGNANCY LOSS

Even after thorough evaluation, half of the women with recurrent miscarriage have no identified predisposing factors. Frequent communication, cautious optimism and emotional support during the first trimester of the next pregnancy have their own therapeutic value. 75 % of women ultimately achieve successful pregnancy. Empiric treatment with exogenous progesterone or aspirin in women with unexplained recurrent pregnancy loss has no proven value.

ENDOCRINE FACTORS

LUTEAL PHASE DEFECT

Early pregnancy depends upon the secretion of progesterone from corpus luteum till 7 weeks of gestational period. Corpus luteal shift do not occur suddenly, it occurs gradually over a period of 7-9 weeks of pregnancy.⁷⁹

The human implantation window is relatively narrow approximately 6-10 days after ovulation. Low levels of circulating progesterone causes delayed endometrial maturation and causes shift in implantation window leading to failed or late implantation. Luteal phase defect is diagnosed when there is a persistent delay of longer than 2 days in the histologic development of the endometrium compared with the respective day of the menstruation.

A low progesterone concentration during early pregnancy reflects defective corpus luteum, an intrinsically abnormal conceptus or both. Serum progesterone concentration fluctuates throughout the day as the corpus luteum progesterone secretion is pulsatile. Measurement of serum progesterone in early pregnancy to assist the quality of luteal function and supporting the risk pregnancy with exogenous progesterone therapy are futile.

Some of the cases of luteal phase defect are associated with hypersecretion of luteinizing hormone (LH). Abnormal LH causes premature aging of oocyte, dyssynchronous maturation of endometrium, improperly timed endometrium at potential implantation sites.⁸⁰ The Luteal phase deficiency

is considered as a subtle form of ovulation dysfunction . Some prefer to treat with exogenous progesterone supplementation starting from 2-3 days after ovulation.⁸¹

POLYCYSTIC OVARIAN DISEASE

Polycystic ovarian disease are not a characteristic feature of a specific endocrine disorder, results from functional derangement in follicular development, or by sustained increased intraovarian androgen levels as a consequence of chronic anovulation.

The National Institute of Child Health and Human Development (NICHD) in 1990.

1. Hyperandrogenism
2. Menstrual dysfunction
3. Exclusion of other disorders having a same clinical presentation .

The European society for Human Reproduction And Embryology (ESHRE) and The American Society Of Reproductive Medicine (ASRM) – Rotterdam criteria -2003, at least two of three major criteria including,

1. Oligo/anovulation
2. Clinical or biochemical signs of hyperandrogenism
3. Polycystic ovaries as identified by ultrasound (total number of follicles, 12 or more measuring 2 – 9 mm in diameter ; ovarian volume > 7 – 7.5 ml)

The overall prevalence of insulin resistance among with PCOS is 50 -75%, greater in obese than in lean individual. Metformin treatment can reduce or eliminate the higher risk of miscarriage in women with PCOS relating to an underlying metabolic disorder.

THYROID HORMONES IN PREGNANCY

Moderate enlargement of thyroid gland by glandular hyperplasia and increased vascularity occurs during pregnancy, but normal pregnancy does not typically cause thyromegaly. In early first trimester, oestrogen increases the synthesis of thyroxine binding globulin. Serum levels of total thyroxine T4 increases beginning from 7 and 9 weeks, and plateau at 18 weeks. Rise in Free serum T4 levels peaks with hCG levels, later returns to baseline . T3 levels starts increasing and reaches peak at 18 weeks later plateaus. TRH levels are not increased during normal pregnancy. TSH

levels get suppressed during pregnancy. This results in failure to diagnose women with early hypothyroidism. Inverse relationship exists between TSH and hCG. TSH levels drop to a nadir at 10 weeks and at the same time hCG reaches the peak. As hCG decreases later, TSH rises in later part of pregnancy. Fetal thyroid gland starts secreting thyroxine only after 10 – 12 weeks of pregnancy, since then the entire supply and fetal brain development depends on maternal source.

Hypothyroidism in pregnancy

Hypothyroidism, even subclinical, has increased risk of spontaneous miscarriage. Mechanism being impaired function of endometrium, corpus luteum and the placenta. Preconceptional screening with achievement of euthyroid state before pregnancy is necessary for successful outcome.

Universal screening is not routinely recommended. But those with elevated TSH levels need estimation of anti thyroid antibodies. Women with positive thyroid antibodies have an increased risk of becoming hypothyroid as pregnancy advances. Women treated for hypothyroidism require an increase in thyroxine during pregnancy starting as early as 5th week of gestation.

The causes for such an effect are

1. estrogen induced increase of thyroid binding globulin,
2. dilutional effect of increase in vascular volume ,
3. and the increase in placental transport and metabolism.

As soon as pregnancy is diagnosed, 30 % increase in levothyroxine dose is required . TSH levels should be monitored monthly and adjust levels in lower limit of normal range for trimester specific levels .

Recurrent pregnancy loss: current perspectives

Over the years, evidence-based treatments such as surgical correction of uterine anomalies or aspirin and heparin for antiphospholipid syndrome have improved the outcomes for couples with recurrent pregnancy loss. However, almost half of the cases remain unexplained and are empirically treated using progesterone supplementation, anticoagulation, and/or immunomodulatory treatments. Regardless of the cause, the long-term prognosis of couples with recurrent pregnancy loss is good, and most eventually achieve a healthy live birth. However, multiple pregnancy losses can have a significant psychological toll on affected couples, and

many efforts are being made to improve treatments and decrease the time needed to achieve a successful pregnancy.

In parallel, epidemiological evidence has shown that the prospects after recurrent miscarriages can be excellent. Moreover, factors derived from the obstetric history, e.g., maternal age and number of preceding miscarriages, independently have a negative impact on the prognosis. Miscarriages have also been linked to subfertility.

Agrawal S et al, (2015) In this study, author studied the pregnancy outcome in patients with history of previous spontaneous abortions.⁸² It is prospective study that included a total of 70 patients with history of previous spontaneous abortion and the patients were observed for complications. The final outcomes were term live birth (74.3%), abortion (14.3%), preterm delivery (8.6%), and still birth (2.8%). Caesarian section was done in 23.3% patients for various indications. They concluded that there is increased risk of abortion, preterm delivery, need for caesarean sections and fetal loss in cases of previous spontaneous abortions.

David.H.Thom et al had evaluated the association between spontaneous abortion and subsequent adverse birth outcomes.⁸³ They concluded that women with three and more spontaneous abortions were at higher risk of preterm < 37 weeks of gestation(**95%**), placenta previa (95%), premature membranes rupture > 24 hours, Breech presentation (95%), congenital malformation (95%).

Eva Alberman et al have compared birth weight of babies in patients with previous live birth and in patients with spontaneous abortion.⁸⁴ The important observations were that the mean birth weights of babies preceding a spontaneous fetal loss was lower than that of live births preceding another live births and that in the subgroup of women with repeated early losses, mean birth weight fell with increasing pregnancy order.

JoaquinE.Paz et al did a study to find out the association between previous fetal loss and fetal malformation and low birth weight in the subsequent pregnancies.⁸⁵ They found out that multiple malformation, Downs syndrome, anencephaly, Spina bifida, Talipus Equinovarus, Congenital dislocation of hip and low birth weight are associated with previous fetal

loss and they finally suggested that abortion or a still birth in a previous pregnancy should be taken into consideration when the risk of malformation or low birth weight in a subsequent pregnancy is assessed.

S.A.Brigham et al did a study to find out how many fetuses continued pregnancy and survived in women with idiopathic recurrent miscarriage.⁸⁶ They also showed that there is decrease in pregnancy success rate with increasing number of previous abortion.

P.W.Reniald, R.W.Beard et al did a study in which they have compared the outcomes of pregnancies progressing beyond 28 weeks of gestation in women with a history of recurrent miscarriage.⁸⁷ Out of the 97 women who had 3 miscarriages 30 percent were small for gestational age, 28 percent were born preterm and perinatal mortality was 161/1000 births, all the parameters are significantly increased above the prevalence for a normal obstetric population.

Eva Alberman, Eve Roman et al The most important observations were that the mean birth weight of babies preceding a spontaneous fetal loss was lower than that of live births preceding another livebirth, and that in

the subgroup of women with repeated early losses, mean birth weight fell with increasing pregnancy order.⁸⁸

M.J.N.C.Keirse, R.W.Rush et al did a study about risk of pre-term delivery in patients with previous pre-term delivery and/or abortion.⁸⁹ Patients with a history of two or more abortion had an increased risk of spontaneous pre-term labour and delivery in future pregnancies. This increased risk related mainly to previous second trimester abortions and not to previous first trimester abortions. Patients with one previous spontaneous pre-term labour and delivery had a 37 per cent risk, and those with two or more pre-term deliveries a 70 per cent risk of again delivering pre-term. There appeared to be no beneficial effect of cervical suture on the incidence of pre-term delivery in these patients.

Ulla Breth Knudsen, Villy Hansen, did a study on the prognosis of a new pregnancy following previous spontaneous abortions.⁹⁰ The risk for a clinical spontaneous abortion in a pregnancy following 0 to 4 consecutive spontaneous abortions was estimated. The overall risk for spontaneous abortion was 11% and the risk for a spontaneous abortion was 16, 25, 45 and 54% after 1 to 4 previous consecutive spontaneous abortions, respectively. For women over 35 years, the risk for spontaneous

abortion was significantly increased, but the almost identical abortion rates after repeated abortions in both young and old women indicate a risk factor which is not age-related.

Eyal Sheiner, Amalia Levy et al did a study to examine the association between spontaneous consecutive recurrent abortions and pregnancy complications such as hypertensive disorders, abruptio placenta, intrauterine growth restriction and cesarean section (CS) in the subsequent pregnancy.⁹¹ A population-based study comparing all singleton pregnancies in women with and without two or more consecutive recurrent abortions was conducted.. Results: Using a multivariate analysis, with backward elimination, the following complications were significantly associated with recurrent abortions—advanced maternal age, cervical incompetence, previous CS, diabetes mellitus, hypertensive disorders, placenta previa and abruptio placenta, mal-presentations and PROM. A higher rate of CS was found among patients with previous spontaneous consecutive recurrent abortions (15.9% versus 10.9%; $P < 0.001$). Another multivariate analysis was performed, with CS as the outcome variable, controlling for confounders such as placenta previa, abruptio placenta, diabetes mellitus, hypertensive disorders, previous CS, mal-presentations,

fertility treatments and PROM. A history of recurrent abortion was found as an independent risk factor for CS (95% ; $P < 0.001$).They concluded that a significant association exists between consecutive recurrent abortions and pregnancy complications such as placental abruption, hypertensive disorders and CS. This association persists after controlling for variables considered to coexist with recurrent abortions. Careful surveillance is required in pregnancies following recurrent abortions, for early detection of possible complications

AIM AND OBJECTIVES

Aim

The aim of our study is to estimate the risk of the Preterm delivery, low birth weight, IUGR, recurrence of abortion, still birth, IUD, PROM or any other adverse outcome in women with history of recurrent pregnancy loss.

Objectives

1. To test the hypothesis that previous unfavourable pregnancy outcome increases the risk of adverse outcome in the present pregnancy.
2. To look for association between previous spontaneous abortion and preterm delivery, low birth weight, IUGR, recurrence of abortion, still birth, IUD, PROM in subsequent pregnancies.

MATERIALS AND METHODS

Sample size- 400 cases

This prospective study was carried out in the Department of obstetrics and gynecology, Thanjavur Medical college and hospital, Thanjavur.

Period of study-.June 2016 to June 2017

Inclusion criteria

1. Cases (200): patients with history of 2 or more spontaneous abortion at less than 20 weeks, irrespective of the period of gestation were included.

Controls (200) :Each Primigravida who delivered or aborted subsequent to each women in case group.

2. Age group-18 to 35 years.

Exclusion criteria

1. Patients with induced abortion
2. History of spontaneous abortion with twin gestation
3. History of ectopic pregnancy.

OBSERVATION AND RESULTS

Study Design:

A Case –control clinical prospective study with 200 patients with history of recurrent pregnancy loss(Cases group) and 200 primigravidae who delivered subsequently to the cases (control group) were undertaken to compare the obstetric outcomes between the two groups.

Table 3: Age distribution of patients

AGE IN YEAR	CONTROL		CASE		COMBINED	
	NO	%	NO	%	NO	%
18-20	10	5	0	0	10	2.5
21-25	120	60	44	22	164	41
26-30	62	31	138	69	200	50
31-35	8	4	18	9	26	6.5
TOTAL	200	100	200	100	400	100
MEAN ± SD	24.02±3.30		27.84±3.36		25.93±3.33	

From table 3, the mean age of patients in case group is 27.84 and control group is 24.02. Indicating that most patients in case group were distributed predominantly in the 26-30 age group whereas patients in control group falls mostly under 21-25 age group.

Fig 1: Age distribution of patients




Table 4: Distribution of cases group with respect to the number of previous abortions.

PREVIOUS HISTORY OF ABORTIONS	NUMBER	PERCENTAGE
2	169	84.5
3	26	13
4	3	1.5
5 or more	2	1
TOTAL	200	100

Table 4 shows the distribution of cases with respect to the number of previous abortions. 84.5% of patients had 2 previous abortions, 13 percent of patients had previous 3 abortions, 1.5 percent of patients had 4 previous abortions and 1 percent of patient had previous 5 or more abortions.

**Fig 2: Distribution of cases group with respect to the number o
previous abortions**




Table 5: Comparison of obstetric outcome between the cases and controls

S.NO	OUTCOME	CONTROL		CASE		P VALUE
		No	%	No	%	
1.	Term	165	89.7	137	82.1	0.04*
2.	Preterm	19	10.3	30	17.9	0.04*
3.	Abortion	14	7	25	12.5	0.124
4.	PROM	11	5.5	28	15.9	0.006*
5.	APH	2	1	6	3	0.284
6.	IUGR	3	1.5	10	5	0.087
7.	Still birth/ IUD	5	2.5	5	2.5	0.999

Table 5 compares the Obstetric outcome between the controls and the cases. The number of patients who reached full term among control group was 89.7% and cases were 82.1% with a p value of 0.04 which is statistically significant . The number of patients who delivered preterm among control group was 10.3% and among cases were 17.9% with a p value of 0.04 that is statistically significant . The percentage of patients who had PROM among control group were 5.5 % and among cases were 14% with a p value of 0.006, which is again statistically very significant

Fig 3: comparison of obstetric outcomes between the groups




Table 6: Mode of termination of pregnancy

MODE OF TERMINATION OF PREGNANCY	CONTROL (n = 200)		CASE (n=200)		P VALUE	STATISTICAL TEST
	NO	%	NO	%		
Abortion	14	7	25	12.5	0.124	Fisher's Exact test
Normal vaginal delivery	138	69	82	41	<0.0001*	Chi square test
Assisted vaginal delivery	8	4	4	2	0.38	Fisher's Exact test
LSCS	40	20	89	44.5	<0.0001*	Chi square test

Table 6 compares the mode of termination of pregnancies between the cases and the controls. 69% of controls had normal deliveries and only 41 % of cases had normal deliveries. 20 percent of controls had LSCS and 44.5% of cases had LSCS. 4 % of controls had assisted vaginal delivery, and 2 % of cases had assisted vaginal delivery. 7 % of controls had early miscarriage and 12.5% percent of cases had early miscarriage.

Figure 4: Mode of termination of pregnancy




Table 7: Indication for LSCS

S. No	Indication for LSCS	Control (n=40)	Cases (n=88)
1	CPD	6 (15%)	12 (13.6%)
2	Fetal Distress	6(15%)	14 (15.9%)
3	PROM/Failed induction	4 (10%)	12 (13.6%)
4	GHT/Failed induction	3 (7.5%)	13 (14.7%)
5	Prolonged pregnancy/ failed induction	5 (12.5%)	0 (0%)
6	Severe oligohydraminos /Failed induction	4 (10%)	4 (4.5%)
7	IUGR with Fetal Distress or abnormal Doppler	2 (5%)	5 (5.68%)
8	Placenta previa	0 (0%)	4 (4.5%)
9	Abruption / unfavourable cervix	2 (5%)	5 (5.68%)
10	Severe Pre-eclampsia/ unfavourable cervix	3 (7.5%)	2 (2.27%)
11	AP Eclampsia/ unfavourable cervix	4 (10%)	6 (6.8%)
12	Others	1 (2.5%)	11 (12.5%)

Table 7 shows the number of patients who have undergone LSCS in case group is more (44.5%) compared to the control group (20%) with a p value of <0.0001. The commonest indication for LSCS in the control group is CPD (15%) and fetal distress(15%) and in the case group is fetal distress (15.9%) and GHT / failed induction (14.7%).

Fig 5: Indication for LSCS




Table 8: Description of frequency of occurrence of complications between the two groups

S. No	Type of complications	Control (n=200)	Cases (n=200)
1	GHT	9 (4.5%)	20 (10%)
2	Severe pre-eclampsia	8 (4%)	5 (2.5%)
3	AP eclampsia	2 (1%)	5 (2.5%)
4	Placenta previa	6 (3%)	4 (2%)
5	Abruption	3 (1.5%)	5 (2.5%)
6	GDM	4 (2%)	10 (5%)
7	Hypothyroidism	4 (2%)	13 (6.5%)
8	Postpartum Hemorrhage	4 (2%)	2 (1%)

Table 8 describes the most common complications that are found in both control group and case group. GHT (10%), GDM (5%) and Hypothyroidism (6.5%) are found to be common among women with history of recurrent pregnancy loss.

Fig 6: Comparison of complications between the groups




Table 9 : Comparison of neonatal outcomes between the groups

S.NO	Neonatal outcome	Control		Cases	
		No	%	No	%
1	Liveborn	180	96.7	172	98.2
2	Deadborn	6	3.3	3	1.8
	Total deliveries	186	100	175	100

Table 9 describes the neonatal outcome between the groups. Of the total 186 deliveries in the control group 180 women (96.7%) had live birth and 6 (3.3%) had dead born. Total number of deliveries in women with recurrent pregnancy loss is 175 of which 172 (98.2%) women had live birth and 3 (1.8%) had dead born.

Figure 7: Comparison of neonatal outcomes between the groups




Table 10 : Comparison of fetal maturity outcomes between the groups

S. No	Parameter	Control (n=180)	Cases (n=173)	P value	Statistical test
1	Pre Term	19 (10.3%)	30 (17.9%)	0.04*	Fisher's Exact test
2	Term	166 (89.7%)	145(82.1%)	0.04*	

Of the total 180 live births in the control group, 19 babies (10.3%) were born preterm and 165 babies (89.7%) were born term .With total 172 livebirths in case group, 30 (17.9%) were born preterm and 145 (82.1%) were born term. Comparison of preterm birth between the controls and cases were statistically significant with a p value of 0.04 .

Fig 8: Comparison of fetal maturity between groups:




Table 11 : Comparison of APGAR score between the two groups

S. No	Apgar score	Control (n=180)	Cases (n=172)	P value	Statistical test
1	Overall score mean with SD	7.64 ± 1.37	7.2 ± 1.9	0.011*	Unpaired t test
2	Median and Mode score	8	8	-----	
Frequency distribution of the Apgar score					
S.No	Score value	Control group (n=180)		Case group (n=172)	
3	Score-4	5 (2.64%)		0 (0%)	
4	Score - 5	2 (1.05%)		12 (6.77%)	
5	Score -6	7 (3.7%)		8 (4.51%)	
6	Score -7	33 (19.5%)		47 (28.3%)	
7	Score-8	108 (59.78%)		94 (54.3%)	
8	Score -9	25 (13.22%)		11 (6.2%)	

(Data are expressed as mean ± SD for overall score and as absolute numbers with percentage for others. * indicates p<0.05 and considered as statistically significant.)

Table 11 describes the comparison of APGAR score between the two groups which is statistically significant with a p value of 0.011. 25 babies (13.2%) in control group and only 11 babies (6.2%) in the case group had APGAR score of 9 and more. The mean APGAR score in control group is 7.6 and that of cases is 7.2.

Table 12: Description of birthweight of the neonates between the groups

S. No	Birth weight range in Kg	Control (n=180)	Cases (n=173)
1	Less than 2.5 Kg	32 (17.3%)	64 (36.4%)
2	Between 2.5 to 3 kg	101 (58.1%)	69 (42.3%)
3	Greater than 3 Kg	47 (24.6%)	40 (21.3%)

Table 12 describes that among the primigravidae , the incidence of low birth weight (< 2.5kg) is 17.3 % whereas in women with history of recurrent pregnancy loss, the incidence of low birth weight is found to be increased (36.4%). This outcome is comparable to other studies by Eva Alberman et al , Joaquin.Paz et al , where they concluded that mean birth weight of babies preceding a spontaneous fetal loss was lower than that of pregnancy following previous live births.

Fig 9: Comparison of birthweight between the two groups





Table 13: Comparison of NICU admission and neonatal death between the groups .

S. No	Neonatal outcome	Control	Cases
	Total NICU admission	34 (18.8%)	60 (34.6%)
1	Discharged	27(79.4%)	47(78.3%)
2	Death (in NICU)	7 (20.6%)	13 (21.6%)

Table 13 compared the number of babies that got admitted in NICU in both control and cases group. Of the 180 live births in control group, 34 babies (18.8%) got admitted and 7 of these babies died in NICU. Of the 173 live births in case group, 60 babies (34.6%) got admitted in NICU and 13 of them died .

Fig 10: comparison of NICU admission between the groups



STATISTICAL METHODS

Chi-square and Fisher Exact test has been used to test the significant proportion of study characteristics between two groups.

1. Chi-Square Test

$$\chi^2 = \frac{\sum (O_i - E_i)^2}{E_i}, \text{ Where } O_i \text{ is Observed frequency and } E_i \text{ is Expected frequency}$$

2. Fisher Exact Test

$$\text{Fisher Exact Test statistic} = \sum p = \frac{(a+b)!(c+d)!(a+c)!(b+d)!}{n!} \frac{1}{\sum a!b!c!d!}$$

3. Significant figures

Suggestive significance $0.05 < P < 0.10$

Moderately significant $0.01 < P < 0.05$

Strongly significant $P < 0.01$

Statistical software:

The Statistical software namely SPSS 11.0, Stata 8.0, Systat 11.0, Medcalc 9.0.1 and Effect Size calculator were used for the analysis of the data and Microsoft word and Excel have been used to generate graphs, tables etc.

DISCUSSION

There were 200 cases of women with history of recurrent pregnancy loss in this study. There were 200 controls comprised of primigravidae who delivered subsequent to in this study. The outcome has been analysed with respect to the following factors

1. Age of the patient
2. Occurrence of complications
3. Obstetric outcome
4. Mode of termination of pregnancy
5. Indication for LSCS
6. Neonatal outcome
7. APGAR score
8. Birth Weight
9. NICU admission

Table 3: Out of the 200 cases and 200 controls. 60 % belonged to 21-25 years of age among the control group and among controls only 22% of patients belonged to the same age group. 31% belonged to 26-30 years

among control group and 69 % belonged to 26 to 30 years among cases group .The age distribution among the cases differ from that of the controls. Women with history of recurrent pregnancy loss has comparatively higher age group than the controls. This may be due to the fact that women with higher maternal age have increased risk of pregnancy loss.

According to M.J.N.C Keirse et al, advanced maternal age is being strongly associated with several adverse maternal and perinatal outcomes.⁸⁹ Another reason for this higher age group among the cases is almost 30 % of women with history of recurrent pregnancy loss in this study had history of taken treatment for infertility.

According to study by Brigham et al (1999) increasing maternal age reduces the chance of a pregnancy success.⁸⁶ Although the confidence intervals for the success prediction are wide at the extreme ends of the age spectrum, there is little doubt that maternal age has a significant impact on future success in the recurrent miscarriage population.

Table 6: Distribution of case group with respect to the number of previous abortions.

Out of the 200 cases studied, 84.5% of patients had history of 2 previous abortions, 13 percent of patients had previous 3 abortions, 1.5 percent of patients had 4 previous abortions and 1 percent of patient had previous 5 or more abortions.

S.No	No. of abortions	Our study (%)	Brigham et al ⁸⁶ (1999) (%)
1	2	84.5	24
2	3	13	48
3	4	1.5	13
4	5	1	14

Table 7 compares the Obstetric outcome between the controls and the cases. The number of patients who reached full term among control group was 89.7% and cases were 82.1%. Ekwo EE et al (1993) in their study of 176 women enrolled showed that percentage of women having prior abortion had less number of patients reaching to successful outcome.⁹²

S.No	Study	% of women who reached full term
1.	Our study	68.5%
2.	Costa et al (2015) ⁹³	75%
3.	Tanya Pradhan et al (2015) ⁹⁴	71.9%
4.	Agrawal S et al (2015) ⁸²	74.3%

The number of patients who delivered preterm among control group was 10.3% and among cases were 17.9% which was statistically significant with p value of 0.04. Similar study done by P.W.Reginald, R.W.Beard (1987) showed that 28 percent of patients having preterm with >3 abortion in the previous pregnancies.⁸⁷ Olga Basso et al showed that there is increased incidence of preterm births in abortion cohort as compared to the reference cohort.⁹⁵

Similarly studies by David H Thom et al, MJNC keirse et al, RW Rush et al, Agrawal et al (2015) showed increased incidence of preterm birth in women with history of recurrent pregnancy loss. In a study by David H Thom et al (1992), adjusted odd ratio for preterm birth is 2.6 (95% CI, 1.7-4) and Makhlaouf MA et al (2014) showed a relative risk of 1.5 (95% confidence interval 1.1-2.1).^{83,96}

S.NO	Study	Incidence of preterm birth
1	Our study	17.9 %
2	Reginald PW et al (1987) ⁸⁷	28%
3	Jivraj et al (2001) ⁹⁷	13%
4.	Tanya Pradhan et al(2015) ⁹⁴	18.5%
5.	Gabbai D et al (2017) ⁹⁸	22.9%
6.	Agrawal et al (2015) ⁸²	-

The percentage of patients who had PROM among control group were 5.5 % and among cases were 14% which is statistically significant with a p value of 0.006. A study by David H Thom et al evaluated the association of history of spontaneous abortion and subsequent adverse birth outcomes. Similar to our study, this study has also showed increased incidence of

PROM in women with recurrent pregnancy loss. Similar study done by Edem E. Ekno et al showed in his study “Previous pregnancy outcome and subsequent risk to preterm rupture of amniotic sac membranes” that previous preterm delivery, abortion and prematurity all increase the risk for subsequent preterm birth with / without PROM.⁹² The Risk of PROM in women with recurrent pregnancy loss were evaluated in the studies by Makhlouf MA et al (2014) (OR 2.9; 95% CI, 1.6-5.3) and David H Thom et al (1992) (RR – 1.8, 95% CI, 1.2 – 2.9).^{83,96}

Percentage of patients having IUGR in our cases group were 5% and which was more than 1.5% among the control group, but there was no statistical difference between these two (P=0.087). The studies done by David.K.Thomas et al showed that risk of IUGR and low birth weight increases as the number of abortions increases.⁸³ With one prior spontaneous abortions 4.9 % and with three or more prior spontaneous abortions it was 9.5%.

S.No	Study	Incidence of IUGR
1.	Our study	5%
2	Tanya Pradhan et al (2015) ⁹⁴	12.8%
3.	Jing Yang (2017) ⁹⁸	11%
4.	Agrawal et al (2015) ⁸²	-

Table 6 compares the mode of termination of pregnancies between the cases and the controls. 69% of controls had normal deliveries and only 41 % of cases had normal deliveries which is statistically significant with a p value of 0.0001.

20 % of controls had LSCS and 44.5 % of cases had LSCS which is also statistically significant with a p value of 0.0001. In a study by Agrawal S et al (2015), they concluded that there is increased need for caesarean section (23.3%) in cases of previous caesarean sections.⁸² 4 % of controls had assisted vaginal delivery, and 2 % of cases had assisted vaginal delivery.

S.No	Study	Incidence of LSCS	P Value
1	Our study	44%	<0.0001
2.	Jivraj et al(2001) ⁹⁶	36%	<0.05
3.	Sheiner E et al (2005) ⁹¹	15.9%	<0.001
4.	Agrawal S et al (2015) ⁸²	23.3%	-
5.	Jing yang et al (2017) ⁹⁸	22%	<0.001
6	Tanya Pradhan et al(2015) ⁹⁴	-	-

7 % of controls had early miscarriage and 12.5% of cases had early miscarriage. This outcome is comparable to the study by Agrawal S et al (2015) , in which the incidence of abortion was found to be 14.3 % .⁸² This is further supported by S A Brigham et al who showed a decrease in pregnancy success rate with increasing number of previous abortion. In a study by Ulla Breth Knudsen et al , the overall risk of spontaneous abortion was 11% and the risk was 16, 25, 45 and 54% after 1 to 4 previous consecutive spontaneous abortions .⁹⁰

S.No	Study	Incidence of abortion
1.	Our study	12.5%
2.	Agrawal S et al (2015) ⁸²	14.3%
3.	Ulla breth Knudsen et al ⁹⁰	11%
4.	Jing Yang et al (2017) ⁹⁸	16%
5.	Tanya Padhan et al(2015) ⁸²	-

Table 7 shows that the commonest indication for LSCS in the control group is Cephalopelvic disproportion (15%) and fetal distress(15%) and in the case group is fetal distress (15.9%) and GHT / failed induction (14.7%). Though the incidence of LSCS is more in women with history of recurrent pregnancy loss, the indications for LSCS and their proportion is almost similar in both groups .

Table 8 describes the most common complications that are found in both control group and case group. In our study, we found that GHT (10%), GDM (5%) and Hypothyroidism (6.5%) are more common among women with history of recurrent pregnancy loss. Other pregnancy complications like IUGR(5%), placenta previa (2%), Abruptio (2.5%) were also found to be increased in case group though not significant. Similarly a study by Eyal Sheiner & Amalia Levy et al, pregnancy complications such as hypertensive disorders , abruptio, IUGR and caesarean section were found to be in a higher rate in women with recurrent abortions.

S.NO	Study	Incidence of complications			
		GHT	Preeclampsia	Placenta Previa	Abruptio
1.	Our study	4.5%	4%	3%	1.5%
2.	Tanya Pradhan et al (2015) ⁹⁴	5.7%	5.7%	-	4.2%
3.	Jing Yang et al (2017) ⁹⁸	17%	24%	21%	3%
4.	David H Thom et al (1992) ⁸³	-	-	6%	-

Table 9 & 10 describes the neonatal outcome between the groups.. Total number of deliveries in women with recurrent pregnancy loss is 175 of which 172 (98.2%) women had live birth and 3 (1.8%) had dead born. Overall the incidence of term live birth in our study is 68.5%. This is similar to the study by Agrawal et al(2015) , the incidence of term live birth was found to be 74.3%.

Table 11 describes the comparison of APGAR score between the two groups which is statistically significant with a p value of 0.011. The mean APGAR score in control group is 7.6 and that of women with recurrent pregnancy loss is 7.2. This was similar to the study by Mona Fawzy et al (2016) showed that women with recurrent miscarriage had significantly increased odds of low Apgar scores at one (odds ratios (OR) 1.57, 95% CI 1.20–2.05) and five minutes (OR 2.0, 95% CI 1.23–3.27).

Table 13 compared the number of babies that got admitted in NICU in both control and cases group . 18.8 % of the babies of control group were admitted in NICU and 34.6 % of the babies of case group got admitted which is very high. The most common cause of admission for these babies are low birth weight and prematurity.

Nearly 50% of Preterm Neonates required NICU admission due to various causes whereas other 50% needed only routine neonatal care. Amongst Term Neonates only 14% required NICU admission and 78.3% were shifted to mother side and given routine neonatal care.

SUMMARY

1. Previous history of recurrent pregnancy loss increases the risk of adverse maternal and perinatal outcome in the future pregnancies.
2. There is association between previous recurrent abortion and preterm delivery(17.9%), Recurrence of abortion(12%) and PROM (14%), in the subsequent pregnancies.
3. There is no statistically significant increase in the rate of IUGR, APH, still birth, IUD in the subsequent pregnancies.
4. There is increased need of caesarean sections for various indications in women with recurrent pregnancy loss. The incidence of LSCS in these women in our study is 44%.
5. History of recurrent pregnancy loss has been associated with low birth weight of the babies in subsequent pregnancy. 36.4 % of the babies of these women in our study have low birth weight (<2.5 kg).

CONCLUSION

RPL is an important reproductive health issue. Various etiologies have been identified over the years and successful therapeutic strategies implemented. A full workup can be initiated following two consecutive losses to identify treatable causes that include uterine abnormalities, APS, endocrine diseases, and balanced translocations. Lifestyle modifications should also be implemented to improve reproductive prognosis. However, almost half of the cases remain unexplained, for which various treatments are continuously being developed. Regardless of the cause, a thorough follow-up with an important psychological support can help most couples achieve a successful live birth. Hence careful surveillance is required in pregnancies following recurrent abortions, for early detection of possible complications.

BIBLIOGRAPHY

1. Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertility and sterility. 2013 Jan 31;99(1):63.
2. Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, Van der Poel S. The international committee for monitoring assisted reproductive technology (ICMART) and the world health organization (WHO) revised glossary on ART terminology, 2009. Human reproduction. 2009 Oct 4;24(11):2683-7.
3. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod. 2006 Sep;21(9):2216-22. Epub 2006 May 17.
4. Royal College of Obstetricians and Gynaecologists, Scientific Advisory Committee, Guideline No. 17. The Investigation and treatment of couples with recurrent miscarriage, 2011.
5. Consensus statement from ESHRE special interest group, Early pregnancy, 2014.
6. Kolte AM, Van Oppenraaij RH, Quenby S, Farquharson RG, Stephenson M, Goddijn M, Christiansen OB, ESHRE Special Interest Group Early Pregnancy. Non-visualized pregnancy losses are prognostically important for unexplained recurrent miscarriage. Human Reproduction. 2014 Mar 6;29(5):931-7.
7. Malpas P, A study of abortion sequence, J Obstet Gynaecol Br Emp

45:932, 1938.

8. Leon speroff et al

9. Roman E, Fetal loss rates and their relation to pregnancy order, J Epidemiol Community Health 38:29, 1984.

10. Regan L, Braude PR, Trembath PL. Influence of post reproductive performance on risk of spontaneous abortion. BMJ 1989;299:541–545

11. Lachmi-Epstein A, Mazor M, Bashiri A. Psychological and mental aspects and "tender loving care" among women with recurrent pregnancy losses. Harefuah. 2012 Nov;151(11):633-7.

12. Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Hum Reprod Update. 2002 Jul-Aug;8(4):333-43.

13. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988;319:189–194.

14. Stephenson MD Frequency of factors associated with habitual abortion in 197 couples. Fertil Steril. 1996 Jul;66(1):24-9

15. ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001.

16. Quenby S, Vince G, Farquharson R, Aplin J, Recurrent miscarriage: a defect in nature's quality control?, Hum Reprod 17:1959, 2002.

17. Jacobsson B¹, Ladfors L, Milsom I. Advanced maternal age and adverse perinatal outcome. *Obstet Gynecol.* 2004 Oct;104(4):727-33.
18. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. *BMJ* 2000; 320: 1708–12.
19. Levi AJ, Raynault MF, Bergh PA, Drews MR, Miller BT, Scott RT, Jr., Reproductive outcome in patients with diminished ovarian reserve, *Fertil Steril* 76:666, 2001.
20. Clifford K¹, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. *Hum Reprod.* 1997 Feb;12(2):387-9
21. Heuser C, Dalton J, Macpherson C, Branch DW, Porter TF, Silver RM. Idiopathic recurrent pregnancy loss recurs at similar gestational ages. *Am J Obstet Gynecol.* 2010 Oct;203(4):343.e1-5.
22. McNamee KM, Dawood F, Farquharson RG. Mid-trimester pregnancy loss. *Obstetrics and Gynecology Clinics.* 2014 Mar 1;41(1):87-102.
23. Simpson JL, Mills JL, Holmes LB, Ober CL, Aarons J, Jovanovic L, Knopp RH, Low fetal loss rates after ultrasound-proved viability in early pregnancy, *JAMA* 258:2555, 1987.
24. Gueneri S, Bettio D, Simoni G, Brambat B, Lanzani A, Fraccaro M, Prevalence and distribution of chromosome abnormalities in a sample of

first-trimester internal abortions, *Hum Reprod* 2:735, 1987.

25. Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?. *Current rheumatology reports*. 2007 Jul 1;9(3):219-25.

26. Warren JE, Silver RM. Genetics of pregnancy loss. *Clinical obstetrics and gynecology*. 2008 Mar 1;51(1):84-95.

27. Suzumori N, Sugiura-Ogasawara M. Genetic factors as a cause of miscarriage. *Current medicinal chemistry*. 2010 Oct 1;17(29):3431-7.

28. Warburton DO, Kline J, Stein Z, Hutzler MI, Chin A, Hassold T. Does the karyotype of a spontaneous abortion predict the karyotype of a subsequent abortion? Evidence from 273 women with two karyotyped spontaneous abortions. *American journal of human genetics*. 1987 Sep;41(3):465.

29. Ogasawara M, Aoki K, Okada S, Suzumori K. Embryonic karyotype of abortuses in relation to the number of previous miscarriages. *Fertility and sterility*. 2000 Feb 29;73(2):300-4.

30. Carp H, Toder V, Aviram A, Daniely M, Mashiach S, Barkai G. Karyotype of the abortus in recurrent miscarriage. *Fertility and sterility*. 2001 Apr 30;75(4):678-82.

31. Lomax B, Tang S, Separovic E, Phillips D, Hillard E, Thomson T, Kalousek DK, Comparative genomic hybridization in combination with Flow cytometry improves results of cytogenetic analysis of spontaneous

abortions, *Am J Hum Genet* 66:1516, 2000.

32. Jaslow CR. Uterine factors. *Obstetrics and Gynecology Clinics*. 2014 Mar 1;41(1):57-86.

33. Grimbizis GF, Camus M, Tarlatzis BC, Bontis JN, Devroey P. Clinical implications of uterine malformations and hysteroscopic treatment results. *Human reproduction update*. 2001 Mar 1;7(2):161-74.

34. Dabirashrafi H, Bahadori M, Mohammad K, Alavi M, Moghadami-Tabrizi N, Zandinejad K, Ghafari V. Septate uterus: new idea on the histologic features of the septum in this abnormal uterus. *American journal of obstetrics and gynecology*. 1995 Jan 1;172(1):105-7.

35. Kupesic S, Kurjak A. Septate uterus: detection and prediction of obstetrical complications by different forms of ultrasonography. *Journal of ultrasound in medicine*. 1998 Oct 1;17(10):631-6.

36. Kupesic S. Clinical implications of sonographic detection of uterine anomalies for reproductive outcome. *Ultrasound in obstetrics & gynecology*. 2001 Oct 1;18(4):387-400.

37. Raga F, Casañ EM, Bonilla-Musoles F. Expression of vascular endothelial growth factor receptors in the endometrium of septate uterus. *Fertility and sterility*. 2009 Sep 30;92(3):1085-90.

38. Valle RF, Ekpo GE. Hysteroscopic metroplasty for the septate uterus: review and meta-analysis. *Journal of minimally invasive gynecology*. 2013 Feb 28;20(1):22-42.
39. Alborzi S, Asadi N, Zolghadri J, Alborzi S, Alborzi M. Laparoscopic metroplasty in bicornuate and didelphic uteri. *Fertility and sterility*. 2009 Jul 31;92(1):352-5.
40. Brucker SY, Rall K, Campo R, Oppelt P, Isaacson K. Treatment of congenital malformations. In *Seminars in reproductive medicine* 2011 Mar (Vol. 29, No. 02, pp. 101-112). © Thieme Medical Publishers.
41. Saravelos SH, Yan J, Rehmani H, Li TC. The prevalence and impact of fibroids and their treatment on the outcome of pregnancy in women with recurrent miscarriage. *Human reproduction*. 2011 Sep 27;26(12):3274-9.
42. Mattson R. The non-expression of MHC class II in trophoblast cells. *AmJ Reprod Immunol* 1998;40:385–394
43. O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. *Trends Cell Biol* 2000;10:542–550.
44. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. *Arthritis Rheum* 2000;43:440–443.
45. Dizon-Townson DS, Melin L, Nelson LM, Varner M, Ward K. 1997. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. *Amer J Obstet Gynecol* 177: 402–405.

46. Grandone E, Margaglione M, Colaizzo D, d'Addeda M, Cappucci G, Vecchione G, Sciannone N, Pavone G, Di Minno G. 1997. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. *Thromb Homeost* 77: 822–824.
47. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA. 1998. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. *Ann Intern Med* 128: 1000–1003.
48. Ren A, Wang J. 2006. Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: A meta-analysis. *Fertil Steril* 86: 1716.
49. Dawood F, Mountford R, Farquharson R, Quenby S. 2007. Genetic polymorphisms on the factor V gene in women with recurrent miscarriage and acquired APCR.
50. Mohamed MA, El Moaty MA, El Kholy AF, Mohamed SA, Ali AL. 2010. Thrombophilic gene mutations in women with repeated spontaneous miscarriage. *Genet Test Mol Biomarkers* 14: 593–597. *Hum Reprod* 22: 546–553.
51. Bogdanova N, Horst J, Chlystun M, Croucher PJP, Nebel A, Bohring A, Markoff A. 2007. A common haplotype of the annexin A5 (*ANXA5*) gene promoter is associated with recurrent pregnancy loss. *Hum Mol Genet* 16: 573–578.

52. Hayashi Y, Sasaki H, Suzuki S, Nishiyama T, Kitaori T, Mizutani E, Sugiu ra-Ogasawara M. 2013. Genotyping analyses for polymorphisms of ANXA5 gene in patients with recurrent pregnancy loss. *Fertil Steril* 100: 1018–1024.
53. Roque H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. 2004. Maternal thrombophilias are not associated with early pregnancy loss. *Thromb Haemost* 91:290–295.
54. Gopel W, Ludwig M, Junge AK, Kohlman T, Diedrich K, Moller. 2001. Selection pressure for the factor-V-Leiden mutation and embryo implantation. *Lancet* 358:1238–1239.
55. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L, Grear IA, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. 2006. Thrombophilia in pregnancy: A systematic review. *Br J Haematol* 132: 171–196.
56. de Jong PG, Goddijn M, Middeldorp S. 2011. Testing for inherited thrombophilia in recurrent miscarriage. *Sem Reprod Med* 29: 540–545.
57. Middeldorp S. 2011. Is thrombophilia testing useful? *Hematol Am Soc Hematol Educ Program* 2011: 150–155.

58. de Jong PG, Goddijn M, Middeldorp S. 2013. Antithrombic therapy for pregnancy loss, *Hum Reprod* 19: 656–673.
59. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, Mercier E, Fabbro-Peray P, Balducchi JP, Mares P, Gris JC. 2014. Comparative incidence of pregnancy outcomes in thrombophilis-positive women from the NOH-APS observational study. *Blood* 123: 414–421.
60. Clark P, Walker ID, Langhorne P, Crichton L, Thomsom A, Greaves M, Whyte S, Greer IA. 2010. SPIN: The Scottish Pregnancy Intervention Study: A multicentre randomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. *Blood* 115: 4162–4167.
61. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, et al. 2010. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. *N Engl J Med* 362: 1586–1596.
62. A. Ekin, C. Gezer, U. Solmaz, C. E. Taner, A. Dogan, and M. Ozeren, “Predictors of severity in primary postpartum hemorrhage,” *Archives of Gynecology and Obstetrics*, vol. 292, no. 6, pp. 1247–1254, 2015.
63. G. Mitić, A. Novakov Mikić, L. Povazan, A. Mitreski, V. Kopitović, and T. Vejnović, “Thromboprophylaxis implementation during pregnancy in women with recurrent foetal losses and thrombophilia,” *Medicinski Pregled*, vol. 64, no. 9-10, pp. 471–475, 2011

- 64.M. A. Rodger, M. T. Betancourt, P. Clark et al., “The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies,” *PLoS Medicine*, vol. 7, no. 6, Article ID e1000292, 2010
- 65.G. Kovalevsky, C. R. Gracia, J. A. Berlin, M. D. Sammel, and K. T. Barnhart, “Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis,” *Archives of Internal Medicine*, vol. 164, no. 5, pp. 558–563, 2004.
66. Donders GG, Van Bulck B, Caudron J, Londers L, Vereecken A, Spitz B, Relationship of bacterial vaginosis and mycoplasmas to the risk of spontaneous abortion, *Am J Obstet Gynecol* 183:431, 2000.
67. Kitaya K. Prevalence of chronic endometritis in recurrent miscarriages. *Fertil Steril*. 2011;95(3):1156–1158.
68. McQueen DB, Perfetto CO, Hazard FK, Lathi RB. Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss. *Fertil Steril*. 2015;104(4):927–931.
- 69.Bouet PE, El Hachem H, Monceau E, Gariépy G, Kadoch IJ, Sylvestre C. Chronic endometritis in women with recurrent pregnancy loss and recurrent implantation failure: prevalence and role of office hysteroscopy and immunohistochemistry in diagnosis. *Fertil Steril*. 2016;105(1): 106–110.

70. Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SE, Horne AW. The role of infection in miscarriage. *Hum Reprod Update*. 2016;22(1):116–133.
71. Metwally M, Ong MKJ, Ledger WL, Li TC, Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception. A meta-analysis of the evidence, *Fertil Steril* 90:714, 2008.
72. Carrell DT, Liu L, Peterson CM, Jones KP, Hatasaka HH, Erickson L, et al. Sperm DNA fragmentation is increased in couples with unexplained recurrent pregnancy loss. *Arch Androl*. 2003;49:49–55.
73. Brahem S, Mehdi M, Landolsi H, Mougou S, Elghezal H, Saad A. Semen parameters and sperm DNA fragmentation as causes of recurrent pregnancy loss. *Urology*. 2011;78:792–6.
74. Ribas-Maynou J, García-Peiró A, Fernandez-Encinas A, Amengual MJ, Prada E, Cortés P, et al. Double stranded sperm DNA breaks, measured by Comet assay, are associated with unexplained recurrent miscarriage in couples without a female factor. *PLoS One*. 2012;7:e44679.
75. Robinson L, Gallos ID, Conner SJ, Rajkhowa M, Miller D, Lewis S, et al. The effect of sperm DNA fragmentation on miscarriage rates: A systematic review and meta-analysis. *Hum Reprod*. 2012;27:2908–17.
76. Ribas-Maynou J, Fernández-Encinas A, García-Peiró A, Prada E, Abad C, Amengual MJ, et al. Human semen cryopreservation: A sperm DNA

fragmentation study with alkaline and neutral Comet assay. *Andrology*. 2014;2:83–7.

77. Dul EC, van Echten-Arends J, Groen H, Dijkhuizen T, Land JA, van Ravenswaaij-Arts CM. Chromosomal abnormalities in azoospermic and non-azoospermic infertile men: Numbers needed to be screened to prevent adverse pregnancy outcomes. *Hum Reprod*. 2012;27:2850–6.

78. Zini A. Are sperm chromatin and DNA defects relevant in the clinic? *Syst Biol Reprod Med*. 2011;57:78–85.

79. Scott R, Navot D, Liu HC, Rosenwaks Z, A human in vivo model for the luteoplacental shift, *Fertil Steril* 56:481, 1991.

80. Watson H, Kiddy DS, Hamilton-Fairley D, et al. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriages. *Hum Reprod* 1993;8:829–833

81. Haas DM, Ramsey PS, Progestogen for preventing miscarriage, *Cochrane Database Syst Rev* 16:CD003511, 2008.

82. Agrawal S, Agrawal V, Suhane R. Pregnancy outcome following spontaneous abortions. *Int J Reprod Contracept Obstet Gynecol* 2015;4:1891-3.

83. David, H.Thom, Lorane, M,Melson, Thomas, “Spontaneous abortion and adverse outcome” *Am.J.Obst.Gynecol* 166(111-116).

84. Alberman.E, Roman .E, Pharoah. “Birth weights before and after spontaneous abortion” Br.J.Obstetric Gynecol, 87:275-280
85. Paz JE, OTANO L, Gadow EC, Castilla EE. Previous miscarriage and stillbirth as risk factors for other unfavourable outcomes in the next pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology. 1992 Oct 1;99(10):808-12.
86. S.A. Brigham, C. Conlon, R.G. Farquharson; A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage, *Human Reproduction*, Volume 14, Issue 11, 1 November 1999, Pages 2868–2871.
87. P.W.Reginald, R.W.Beard “Outcome of pregnancies progressing beyond 28 weeks of gestation in women with a history of recurrent miscarriage” Br.Jr of Obst Gyna 1987, July 94, P-643-648.
88. M J. N. C. Keirse, R. W. Rush, A. B. M. Anderson, A. C. Turnbull (1978)kris of pre-term delivery in patients with previous pre-term delivery and/or abortion BJOG: An International Journal of Obstetrics and Gynaecology 85(2), 81–85.
89. Ulla Breth Knudsen, Prognosis of a new pregnancy following previous spontaneous abortions, European Journal of Obstetrics & Gynecology and Reproductive Biology Volume 39, Issue 1, 21 March 1991, Pages 31-36.

90. E. Sheiner, A. Levy, M. Katz, and M. Mazor, "Pregnancy outcome following recurrent spontaneous abortions," *European Journal of Obstetrics Gynecology and Reproductive Biology*, vol. 118, no. 1, pp. 61–65, 2005.
91. Eden.E, Capol. "Previous pregnancy outcome and subsequent risk of preterm premature rupture of amniotic sac " *Jr.Obst.and Gyn.* June 1993, Vol 100(536-554)
92. Costa OL, Santos EM, Jesus VS, Netto EM. Reproductive outcome in pregnant women with recurrent pregnancy loss. *Revista Brasileira de Ginecologia e Obstetrícia*. 2015 Dec;37(12):578-84.
93. Pradhan T, Dilip PB. An observational study of maternal and perinatal outcome in patients of recurrent pregnancy loss in rural population. *International J. of Healthcare and Biomedical Research*. 2015 Jan;3(02):91-101.
94. Olga Basso, Jorn Oben, "Low birth weight and preterm birth weight after short interpregnancy interval" *Am.jr of Obstet & Gynecol*. 1998. Vol.178.
95. Makhlouf, M. A., Clifton, R. G., Roberts, J. M., Myatt, L., Hauth, J. C., Leveno, K. J., ... Sorokin, Y. (2014). Adverse pregnancy outcomes among women with prior spontaneous or induced abortions. *American Journal of Perinatology*, 31(9), 765-772.

96. Jivraj S, Anstie B, Cheong YC, Fairlie FM, Laird SM, Li TC. Obstetric and neonatal outcome in women with a history of recurrent miscarriage: a cohort study. *Human Reproduction*. 2001 Jan 1;16(1):102-6.
97. Gabbai D, Harlev A, Friger M, Steiner N, Sergienko R, Kreinin A, Bashiri A. Pregnancy outcomes among patients with recurrent pregnancy loss and uterine anatomic abnormalities. *Journal of Perinatal Medicine*. 2017 Jul 25.
98. Jing Yang, Yan Wang, Xiao-ye Wang, Yan-yu Zhao, Jing Wang, and Yang-yu Zhao, "Adverse Pregnancy Outcomes of Patients with History of First-Trimester Recurrent Spontaneous Abortion," *BioMed Research International*, vol. 2017, Article ID 4359424, 7 pages, 2017.

PROFORMA

Name:

Age:

IP.No:

Occupation :

Address:

Date of admission:

Date of Discharge:

MENSTRUAL HISTORY:

Age at Menarche:

Cycles: Regular/Irregular:

LMP:

MARITAL HISTORY:

Married for

Consanguinity:

Treatment for infertility

OBSTETRIC CODE:

PREVIOUS OBSTETRIC HISTORY:

PRESENT PREGNANCY:

LMP:

EDD:

1st trimester

2nd trimester

3rd trimester

PAST HISTORY: Diabetes / hypertension/ renal disease/ SLE/
rheumatoid arthritis/ cardiac disease/ asthma / epilepsy/ others

SURGICAL HISTORY:

FAMILY HISTORY:

PERSONAL HISTORY:

HUSBAND:

Age:

Occupation:

Smoking/alcohol:

GENERAL EXAMINATION:

Height:

Weight :

BMI :

Breast:

Thyroid :

BP :

Pulse:

Cvs/Rs:

P/A:

P/V:

INVESTIGATIONS

Hb%

Urine Routine

Blood sugar:

S.urea:

S.creatinine:

Blood group:

VDRL:

HIV:

HBsAg:

Pelvic Ultrasonogram:

SPECIFIC INVESTIGATIONS:

Glucose Tolerance Test:

Thyroid Stimulating Hormone:

APLA screening (if done)

Obstetric outcome:

Abortion:

Spontaneous expulsion:

Preterm:

PROM

Term:

Post term:

IUGR:

IUD/STILL BIRTH:

MODE OF DELIVERY:

Normal vaginal delivery:

Assisted breech delivery:

Assisted deliveries:

Duration of labour:

LSCS:

Indication:

BABY DETAILS:

Sex:

Weight:

Apgar score:

NICU Admission:

Outcome:

COMMENTS:

PATIENT CONSENT FORM

Study Detail: A Study on “MATERNAL AND PERINATAL OUTCOME
IN PREGNANCY FOLLOWING RECURRENT PREGNANCY LOSS”

Study Centre: Department of Obstetrics & Gynaecology, Thanjavur
medical college, Thanjavur.

I confirm that I have read and understood the information Sheet for
the above study. I have had the opportunity to ask questions and all my
questions and doubt have been answered to my complete satisfaction.

I understand that my participation in the study is voluntary and that
i am free to withdraw at an time, without giving any reason, without my
legal rights being affected.

I understand that the Clinical study personnel, the Ethics Committee
and the Regulatory Authorities will not need my permission to look at my
health records both in respect to the current study and any further research
that may be conducted in relation to it, even if i withdraw from the study.
I agree to this access. However, I Understand that my identity will not be
revealed in any information released to third parties or published, unless
as required under the law. I agree not to restrict the use of any data or
results that arise from this study.

I agree to take part in the above study and to comply with the
instructions given during the study and to faithfully co-operate with the
study team, and to immediately inform the study if I suffer from any
deterioration in my health of well being or any unexpected or unusual
symptoms.

I hereby give permission to undergo completed clinical examination
and diagnostic tests including haematological, biochemical, radiological
tests.

I hereby consent to participate in this study.

Signature/Thumb impression:..... Place Date
of the patient

Patient's Name, Address & Ph.No:.....

Name of the Investigation:.....

Signature of the Investigator: Place.....Date

Institution :

Signature of the Relative/Gardian.....

MASTER CHART

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Age	NEONATAL OUTCOME							
	Maturity	Term	Sex	APGAR	Birth Weight			NICU Admission
					<2.5Kg	2.5-3 (kg)	>3kg	
22	✓		F	8		2.7		·
23	✓		M	4		2.8		✓
21	✓		M	8			3.5	
24	✓		M	8			3.5	
22			M	6	1			✓
30	✓		M	7			3.25	
21	✓		F	8		2.25		
26	✓		M	8			3.25	
30	✓		F	9	2.2			
26	✓		F	8		2.8		
24	✓		F	8			3	
25	✓		M	7		2.9		
21	✓		M	8			3.2	
29	✓		M	7	2.2			✓
23	✓		F	7	2			✓
23	✓		M	7	2.3			
29	✓		M	8			2.75	
22	✓		M	8		2.5		
27	✓		M	9		2.6		
29	✓		M	8			3	
21	✓		F	9	2.4			
28	✓		M	8		2.6		
27	✓		F	8			3.6	
30			F	7	2.1			
25	✓		F	8		2.7		
24	✓		M	7		2.6		✓
32			-					
22	✓		F	8			3.4	
24	✓		F	9	2.4			
24	✓		F	8			3.4	
27	✓		F	7		2.7		
25	✓		M	8			3	
26	✓		F	8		2.9		

Age	NEONATAL OUTCOME							
	Maturity	Term	Sex	APGAR	Birth Weight			NICU Admission
					<2.5Kg	2.5-3 (kg)	>3kg	
30	✓		M	8			3.1	
35	✓		M	8		2.7		
22	✓		M	9		2.5		
29	✓		F	8			3.5	
27	✓		M	8		2.6		
25	✓		M	9		2.6		
25	✓		F	6			3	✓
26			F	6	1			✓
24	✓		M	7		2.5		✓
22	✓		M	8		2.7		✓
24	✓		M	7	1.9			✓
28	✓		F	7		2.5		✓
26			M	7	2.2			✓
27			M	8	2.3			
24	✓		F	8			3.2	
25	✓		M	9			3	
23	✓		M	8		2.8		
26			-					
26	✓		F	-	2.2			✓
31	✓		M	8		2.8		
27	✓		M	8		2.5		
37	✓		F	8		2.9		
27	✓		F	7			3	
27	✓		M	8		2.8		
23	✓		M	8		2.9		
25	✓		M	9		2.6		
26	✓		F	8		2.5		✓
23	✓		M	8		2.5		
27								
26	✓		F	9		2.9		
26	✓		F	8		2.7		
25	✓		M	8		2.6		
27	✓		F	8		2.5		
28	✓		M	8		2.8		
24	✓		F	8			3	
24	✓		M	7			3.2	
25	✓		M	8		2.8		
27	✓		F	9		2.8		
27			-					

Age	NEONATAL OUTCOME							
	Maturity	Term	Sex	APGAR	Birth Weight			NICU Admission
					<2.5Kg	2.5-3 (kg)	>3kg	
25			M	7	1.8			<
29	✓		M	8		2.7		<
25	✓		M	8			3.4	
24			F	7		2.7		
25			-					
27	✓		M	8		2.9		
26	✓		F	8		2.6		
25	✓		F	7		2.6		✓
25	✓		M	8	2.4			✓
27	✓		M	6	2			
24	✓		M	8		2.8		
25			F	5	800g			✓
26	✓		M	7		2.8		
32			F	8		2.9		
30	✓		M	9			3	
25	✓		M	8		2.9		
25	✓		M	8		2.7		
25	✓		M	7	2			✓
27			-					
27	✓		F	8		2.8		
25	✓		M	8		2.9		
23	✓		M	8			3.2	
33	✓		M	8		2.6		
25	✓		M	7		2.7		
27	✓		F	8		2.9		
29	✓		F	8		2.8		
28	✓		M	8		2.9		
28			F	7			3.2	✓
27			M	7	2.1			✓
34	✓		F	8		2.8		
33			M	8		2.5		
24	✓		M	8			3.2	
27	✓		F	8		2.8		
27	✓		M	9			2.5	
28			M	-	600g			
27	✓		F	8		2.8		
30	✓		M	8		2.9		
26	✓		F	8		2.5		
25	✓		F	7		2.4		

Age	NEONATAL OUTCOME							
	Maturity	Term	Sex	APGAR	Birth Weight			NICU Admission
					<2.5Kg	2.5-3 (kg)	>3kg	
20	✓		M	8			3	
28	✓		F	8			3.2	
20	✓		F	8		2.9		
20	✓		M	8		2.8		
25	✓		F	9		2.8		
28			M	7	1.9			✓
30	✓		M	8		2.8		
27			M	8		2.9		
28	✓		F	7			3.4	✓
26	✓		M	9			3	
25			-					
29	✓		F	8		2.8		
27			M	6	1			✓
30	✓		M	8		2.7		
32	✓		F	8			3	
28	✓		M	8		2.9		
27	✓		M	8		2.9		
27	✓		F	8		2.8		
20	✓		F	8		2.5		
25	✓		M	8		2.9		
29	✓		M	8	2.4			✓
27			F	7	2.2			✓
24	✓		M	8		2.8		
26	✓		M	8		2.5		
26	✓		F	8		2.4		
28	✓		M	9		2.9		
25	✓		M	7			3.5	
27			F	-	400g			
24	✓		F	8		2.8		
26	✓		M	8		2.9		
27	✓		M	9		2.8		
29	✓		F	8		2.5		
30	✓		M	7		2.8		✓
25	✓		M	8		2.9		
26	✓		M	9		2.8		
22	✓		F	8		2.6		
25	✓		M	7		2.5		
27			F		100g			

Age	NEONATAL OUTCOME							
	Maturity	Term	Sex	APGAR	Birth Weight			NICU Admission
					<2.5Kg	2.5-3 (kg)	>3kg	
30	✓		F	8		2.9		
28	✓		F	8		2.6		
22			F	7	2.1			✓
25	✓		M	8	2.4			
28	✓		M			2.8		
30	✓		M	8			3	
24	✓		F	8		2.5		
29	✓		F	7		2.8		
29	✓		M	8		2.9		
27	✓		M	9		2.5		
27	✓		M	8	2.4			
29			F	5	1.1			✓
27	✓		M	8		2.9		
26	✓		M	7			3.3	

Age	NEONATAL OUTCOME							
	Maturity	Term	Sex	APGAR	Birth Weight			NICU Admission
					<2.5Kg	2.5-3 (kg)	>3kg	
25	✓		M	8			3	
20	✓		F	7			3.8	✓
33	✓		F	7		2.8		✓
24	✓		M	9		2.7		
26	✓		M	8			3.2	
28	✓		F	8		2.9		
27	✓		F	8		2.5		
25	✓		M	8			3.4	
29			F	7	2.1			✓
24	✓		M	9			3.2	
20	✓		F	8			3	
28			M	8		2.7		
28	✓		F	8		2.6		
27	✓		M	7		2.9		
28	✓		F	9			3.2	
26	✓		M	8		2.6		
25	✓		M	8		2.5		
25			F	-	200g			
23	✓		M	9		2.8		
28			-					
27	✓		M	8		2.6		
30	✓		F	8		2.5		
25	✓		F	8		2.8		
24	✓		F	8		2.5		
27	✓		M	6			3.3	✓
27	✓		F	9		2.7		
29	✓		M	9			3.2	
25			-					
30	✓		M	8			3	
22	✓		M	8		2.8		✓
25	✓		F	8		2.9		
28	✓		M	8		2.8		
28			M	8			3.1	
24	✓		F	9			3	
22	✓		M	7			3.5	✓
30	✓		F	8		2.8		
28			M	6	2			✓

[illegible]

[illegible]

S.No	Name	Age	IPNo	Booking Status	Menstrual History		MARITAL H/O (YEARS)	CONSANGUINITY	Obstetric H/o	Gestational Age (Weeks)	OBSTETRIC OUTCOME						MODE OF DELIVERY														CO				
											Abortion	Preterm Labour	PROM	APH	IU/G R	IUD/Stillbirth	Normal Vaginal	Assisted Vaginal	LSCS	INDICATION FOR ISCS															
																				CPD	Fetal Distress	PROM/Failed Induction	GHT/Failed Induction	Postdated failed Induction	severe Oligo/Fetal Distress	TUG/Fetal distress/ Abnormal Doppler	Placenta previa	Abruption	Severe Preeclampsia	AP Eclampsia		Others	GHT		
35	Ponnumani	23	472404	B	R	3	NCM	G ₃ A ₂	38							✓																			
36	Shanthi	28	473162	B	R	5	NCM	G ₃ A ₂	37								✓																✓		
37	kolanjiyamual	27	477917	UB	R	8	CM	G ₉ A ₈	8	✓																									
38	Nadhiya	30	472133	UB	R	3	NCM	G ₄ A ₃	38						✓																				
39	Sasikala	26	473639	B	R	3	NCM	G ₃ A ₄	38								✓		✓																
40	Sheela Mary	30	473747	B	IR	2	NCM	G ₃ A ₂	39																										
41	Rubini	26	474481	UB	R	3	NCM	G ₄ A ₃	38			✓					✓			✓															
42	Deepita	25	475486	B	R	2	NCM	G ₃ A ₂	38						✓																				
43	Manjula	20	475581	B	R	2	NCM	G ₃ A ₂	39						✓																				
44	Devika	28	475578	UB	IR	3	NCM	G ₄ A ₃	40								✓																		
45	Gayathri	20	475620	B	R	2	CM	G ₄ A ₃	39						✓																				
46	Shanthi	20	475838	B	IR	2	NCM	G ₃ A ₂	40								✓																	✓	
47	Rajesh ari	25	475406	UB	R	2	NCM	G ₃ A ₂	40			✓					✓																	✓	
48	Usharani	28	476192	B	R	3	CM	G ₃ A ₂	38						✓																				
49	Senganval	30	478219	UB	R	7	NCM	G ₃ A ₂	7	✓																									
50	Saranya	27	474900	B		3	NCM	G ₄ A ₃	38								✓				✓													✓	
51	Kaliyamal	28	473591	UB	R	4	NCM	G ₄ A ₃	34			✓			✓		✓																		
52	Priya	23	473823	B	IR	3	NCM	G ₃ A ₂	37						✓																				
53	Amalarani	24	478204	UB	R	4	NCM	G ₄ A ₃	20						✓																				
54	Thirumalai selvi	23	467902	B	IR	3	NCM	G ₃ A ₂	40						✓																				
55	Vasumathy	28	468015	UB	R	2	NCM	G ₃ A ₂	28			✓					✓																	✓	
56	Menaka	24	469910+	UB	R	3	NCM	G ₃ A ₂	26	✓																									
57	Priyanka	21	451968	B	R	3	CM	G ₄ A ₃	37						✓																				
58	kokila	25	451827	B	R	2	NCM	G ₃ A ₂	37								✓		✓															✓	
59	Bhuvanesh ari	28	451412	B	R	3	NCM	G ₄ A ₃	40						✓																				
60	Prema	20	401318	B	R	2	NCM	G ₄ A ₃	38						✓																				
61	Sumathy	22	451396	B	R	3	NCM	G ₃ A ₂	40								✓		✓																
62	Lavanya	23	451010	UB	IR	2	NCM	G ₄ A ₃	36					✓			✓																		
63	Jenitta	24	450499	B	R	3	CM	G ₄ A ₃	39						✓																				

S.No	Name	Age	IPNo	Booking Status	Menstrual Histroy	MARITAL H/O (YEARS)	CONSANGUINITY	Obstetric H/o	Gestational Age (Weeks)	OBSTETRIC OUTCOME						MODE OF DELIVERY														CO				
										Abortion	Preterm Labour	PROM	APH	IU/GR	IUD/Stillbirth	Normal Vaginal	Assisted Vaginal	LSCS	INDICATION FOR ISCS															
																			CPD	Fetal Distress	PROM/Failed Induction	GHT/Failed Induction	Postdated failed Induction	severe Oligo/Fetal Distress	TUG/Fetal distress/ Abnormal Doppler	Placenta previa	Abruptio	Severe Preeclampsia	AP Eclampsia		Others	GHT		
64	Tamilselvi	26	450332	B	R	5	NCM	G ₃ A ₂	38 6d								✓																	
65	Suganya	24	450233	B	R	4	NCM	G ₃ A ₂	39			✓					✓			✓														
66	Hemalatha	30	449964	B	IR	3	NCM	G ₄ A ₃	40								✓				✓													✓
67	Suriya	25	449526	B	R	2	NCM	G ₄ A ₃	39								✓	✓																
68	Kanmani	25	449533	B	R	4	NCM	G ₃ A ₂	40 5d								✓		✓															
69	Jegadeesh ari	22	449536	B	R	2	NCM	G ₃ A ₂	40								✓			✓														✓
70	Getsiyal	22	449007	UB	R	6	NCM	G ₃ A ₂	37 2d				✓				✓														✓			
71	Mariyammal	25	448498	B	R	5	NCM	G ₃ A ₂	38 4d																									
72	Usha	35	442427	B	R	4	NCM	G ₃ A ₂	39								✓																✓	
73	Muthulakshmi	27	446929	B	R	2	NCM	G ₃ A ₂	38 5d								✓				✓													
74	Sathiya	23	407078	B	R	3	NCM	G ₃ A ₂	40					✓																				
75	Sasikala	30	446910	B	IR	2	NCM	G ₃ A ₂	38								✓				✓													✓
76	Mahes ari	29	446278	B	R	2	NCM	G ₃ A ₂	35								✓								✓									
77	Suganya	23	446757	B	R	4	NCM	G ₃ A ₂	39								✓																	
78	Thamaraiselvi	23	446646	B	R	2	NCM	G ₃ A ₂	39					✓																				
79	Selvi	30	446435	B	R	3	NCM	G ₃ A ₂	37					✓																				
80	Shivashakthi	27	446248	B	R	5	NCM	G ₃ A ₂	39								✓	✓																
81	Revathy	31	445952	B	R	8	NCM	G ₃ A ₂	40								✓																✓	
82	Muthulakshmi	29	448126	B	R	6	NCM	G ₄ A ₃	33					✓																				
83	Kaveri	28	451241	UB	IR	3	NCM	G ₄ A ₃	38				✓				✓																	
84	Kasiyammal	27	449260	UB	R	2	NCM	G ₃ A ₂	11		✓																							
85	Saroja	24	441701	B	R	1	CM	G ₃ A ₂	38			✓			✓																			✓
86	Poovazhagi	29	441812	B	R	4	NCM	G ₃ A ₂	29					✓																				
87	Ganathy	30	446104	B	IR	3	NCM	G ₄ A ₃	38								✓								✓									✓
88	Sivaranjani	32	448471	B	IR	7	CM	G ₆ A ₅	36			✓			✓																			
89	Savithri	22	449042	B	R	2	CM	G ₃ A ₂	37			✓					✓			✓														
90	Bharathi	25	451012	UB	R	2	NCM	G ₃ A ₂	40					✓																				

S.No	Name	Age	IPNo	Booking Status	Menstrual Histroy	MARITAL H/O (YEARS)	CONSANGUINITY	Obstetric H/o	Gestational Age (Weeks)	OBSTETRIC OUTCOME						MODE OF DELIVERY														CO				
										Abortion	Preterm Labour	PROM	APH	IU/GR	IUD/stillbirth	Normal Vaginal	Assisted Vaginal	LSCS	INDICATION FOR ISCS															
																			CPD	Fetal Distress	PROM/Failed Induction	GHT/Failed Induction	Postdated failed Induction	severe Oligo/Fetal Distress	IUGR/Fetal distress/ Abnormal Doppler	Placenta previa	Abruptio	Severe Preeclampsia	AP Eclampsia		Others	GHT		
91	Mahathi	25	454404	B	R	2	CM	G ₃ A ₂	10	✓																								
92	Ezhilarasi	24	453721	UB	IR	3	CM	G ₃ A ₂	35		✓					✓																		
93	Keerthiga	28	453810	B	R	4	CM	G ₃ A ₂	39			✓				✓			✓															
94	Roja	27	457410	B	R	3	CM	G ₄ A ₃	39																									
95	Tamilarasi	27	456892	B	R	1	CM	G ₃ A ₂	26	✓																								
96	Bhuvanesh ari	25	454471	B	R	2	NCM	G ₃ A ₂	38			✓				✓																		
97	Ambika	26	447409	UB	R	3	NCM	G ₃ A ₂	37				✓					✓										✓						✓
98	Latha	23	452172	UB	IR	2	NCM	G ₃ A ₂	39							✓																		
99	Suraya Priyadharshini	22	451404	B	IR	1	NCM	G ₃ A ₂	38							✓																		
100	Anuradha	24	461289	B	R	2	NCM	G ₃ A ₂	40	✓								✓																
101	Gayathri	28	461742	UB	R	2	NCM	G ₃ A ₂	38							✓																		
102	Renganayagi	25	465066	B	IR	2	CM	G ₃ A ₂	39							✓																		
103	Archana	27	461414	B	R	3	NCM	G ₃ A ₂	30		✓							✓																
104	Kumudhavalli	24	462525	B	R	3	NCM	G ₃ A ₂	37							✓																		
105	Poojakumari	22	460777	B	R	4	NCM	G ₃ A ₂	9	✓																								
106	Nivedhita	29	469786	UB	R	4	CM	G ₃ A ₂	37									✓																
107	Kalpana	22	466863	B	R	3	NCM	G ₄ A ₃	11	✓			✓															✓						
108	Ragini	34	466421	B	IR	3	NCM	G ₃ A ₂	38							✓																		
109	lallitha	25	467645	UB	R	2	NCM	G ₃ A ₂	39			✓				✓																		
110	Neelavathy	27	462314	B	R	2	NCM	G ₃ A ₂	38									✓																
111	Rosy	25	465613	B	R	2	NCM	G ₃ A ₂	39								✓																	✓
112	Kaladevi	25	466840	B	R	3	CM	G ₃ A ₂	38									✓																
113	Vasantha	24	467356	UB	IR	5	CM	G ₃ A ₂	28		✓		✓		✓			✓											✓					
114	Dhanalakshmi	29	468115	B	R	7	NCM	G ₄ A ₃	39							✓																		
115	Poongodi	25	469562	B	R	3	NCM	G ₃ A ₂	39							✓																		
116	Lakshmipriya	26	463100	B	R	2	NCM	G ₃ A ₂	27	✓																								
117	kousalya	20	464567	B	R	2	NCM	G ₄ A ₃	38			✓						✓									✓							
118	Pavithra	23	461214	B	R	3	NCM	G ₃ A ₂	38							✓																		
119	Poovizhi	25	462501	B	R	3	NCM	G ₃ A ₂	39							✓																		

S.No	Name	Age	IPNo	Booking Status	Menstrual Histroy	MARITAL H/O (YEARS)	CONSANGUINITY	Obstetric H/o	Gestational Age (Weeks)	OBSTETRIC OUTCOME						MODE OF DELIVERY																	CO																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
										Abortion	Preterm Labour	PROM	APH	IUGR	IUD/Stillbirth	Normal Vaginal	Assisted Vaginal	LSCS	INDICATION FOR ISCS																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											
																			CPD	Fetal Distress	PROM/Failed Induction	GHT/Failed Induction	Postdated failed Induction	severe Oligo/Fetal Distress	IUGR/Fetal distress/ Abnormal Doppler	Placenta previa	Abruptio	Severe Preeclampsia	AP Eclampsia	Others	GHT																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
120	Chithra	25	466145	UB	R	4	NCM	G ₃ A ₂	38																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					

[illegible]

S.No	MPPLICATIONS							NEONATAL OUTCOME									
	Antepartum							Maturity			Birth Weight			NICU Admission	Discharged	Neontal death	
	Severe Preeclampsia	AP Edampsia	Placenta Previa	Abruptio	GDM	Hypothyroid	PPH	Preterm	Term	Sex	Apgar Score	<2.5kg	2.5-3 (kg)	>3kg			
1								✓		M	7	1.2			✓		✓
2						✓			✓	F	8			3.5	-		
3								✓		M	8			3.3	-		
4									✓	M	7			3.1	✓	✓	
5		✓							✓	M	7	1.6			✓	✓	
6	✓								✓	F	8		3		-		
7																	
8									✓	M	9		3		-		
9									✓	F	8		3]		-		
10									✓	F	8	2			✓	✓	
11								✓		M	7	1.75			✓	✓	
12										M	8		2.9				
13										M							
14										F	8		2.6		✓	✓	

S.No	MPLICATIONS							NEONATAL OUTCOME									
	Antepartum							Maturity			Birth Weight			NICU Admission	Discharged	Neontal death	
	Severe Preeclampsia	AP Eclampsia	Placenta Previa	Abruptio	GDM	Hypothyroid	PPH	Preterm	Term	Sex	Apgar Score	<2.5kg	2.5-3 (kg)	>3kg			
15									F	8	2.1			✓	✓		
16									F	8	2.3			-			
17			✓						M	-			500g	-	-	✓	
18									M	7		3.2		✓	✓	-	
19									M	8		2.5		-		-	
20									F	7	1.75			✓	✓		
21									M	8		3.25		✓	✓		
22					✓				F F	8 7		2.5 2.6		-	-		
23									-								
24									F	8		2.6		-		-	
25		✓							M	7	2.4			✓	✓		
26									F	8	2.2			✓	✓		
27						✓		✓	M	8		3		-	-		
28									-								
29								✓	F	7	2			-	-		
30								✓	F	8		2.9		-	-		
31								✓	M	8			3.4	✓	✓		
32								✓	F	8			3.5	-	-		
33								✓	F	8		2.8					
34								✓	F	9		2.5		-	-		

S.No	MPICATIONS							NEONATAL OUTCOME									
	Antepartum							Maturity			Birth Weight			NICU Admission	Discharged	Neontal death	
	Severe Preeclampsia	AP Eclampsia	Placenta Previa	Abruptio	GDM	Hypothyroid	PPH	Preterm	Term	Sex	Apgar Score	<2.5kg	2.5-3 (kg)	>3kg			
35									✓	M	8		2.8				
36									✓	M	7			3.4	✓	✓	
37										-	-						
38									✓	F	8	2.5					
39									✓	M	8	2.5			✓	✓	
40									✓	M	8		2.75				
41									✓	F	8			3.75			
42									✓	M	9		2.7				
43									✓	F	8		2.6				
44									✓	M	9			3.75			
45									✓	M	8		2.6				
46									✓	F	7			3	✓	✓	
47									✓	M	6			3	✓	✓	
48									✓	M	7	2.2					
49										-							
50						✓			✓	M	8			3.3	-	-	
51				✓				✓		M	7	1.9			✓	✓	
52						✓			✓	F	8	2.4			-	-	
53									✓	M	-	900g 800g					✓ ✓
54									✓	F	8	2.3					
55				✓				✓		F		900g			✓		✓
56								✓		M	6	800g					✓
57									✓	M	8		2.75				
58									✓	M	8		2.95				
59									✓	M	8			3.2			
60									✓	M	9			3.4			
61									✓	M	8		2.9				
62								✓		F	7	2.4			✓	✓	
63									✓	M	8			3.05			

S.No	MPICATIONS							NEONATAL OUTCOME									
	Antepartum							Maturity			Birth Weight			NICU Admission	Discharged	Neontal death	
	Severe Preeclampsia	AP Eclampsia	Placenta Previa	Abruptio	GDM	Hypothyroid	PPH	Preterm	Term	Sex	Apgar Score	<2.5kg	2.5-3 (kg)	>3kg			
64								✓	M	7		2.65		✓	✓		
65						✓		✓	M	8			3				
66						✓		✓	F	8	2.2						
67								✓	M	8			3.3				
68								✓	F	7			3.6	✓	✓		
69								✓	F	7			4.1	✓	✓		
70		✓						✓	M	7	2			✓	✓		
71								✓	F	8	2.5						
72								✓	M	8			3.5				
73								✓	F	7	2.15						
74								✓	M	8		2.8					
75								✓	M	8		2.75					
76							✓		M	8	2.1			✓	✓		
77		✓						✓	M	8		2.6		✓	✓		
78								✓	M	8		2					
79								✓	M	8			3.1				
80								✓	M	8			3.5				
81								✓	F	7			3.3				
82							✓		F	7	2			✓	✓		
83			✓					✓	M	6		2.7		✓	✓		
84								-									
85						✓		✓	M	7	2.4						
86							✓		F	-	800g	-		✓		✓	
87								✓	F	7	2			✓	✓		
88							✓		F	8	2.2			✓	✓		
89								✓	M	7		2.6		✓	✓		
90								✓	M	8		2.8					

S.No	MPICATIONS							NEONATAL OUTCOME											
	Antepartum							Maturity			Sex			Birth Weight			NICU Admission	Discharged	Neontal death
								Severe Preeclampsia	AP Eclampsia	Placenta Previa	Abruptio	GDM	Hypothyroid	PPH	Preterm	Term			
91								✓	-	7	1.5			✓		✓			
92							✓		M	8		2.9		-	-				
93				✓				✓	M	8		2.7							
94								✓	F	7	800					✓			
95								✓	M	8	2.2								
96				✓		✓		✓	F	7	2			✓	✓				
97								✓	M	8		2.7							
98								✓	M	8		2.6		✓	✓				
99					✓			✓	M	8	1.9			✓	✓				
100								✓	M	8		2.8							
101								✓	F	8		2.6							
102	✓						✓		M	5	900g			✓		✓			
103								✓	M	7	2.3								
104						✓			-										
105			✓					✓	M	7	2.7								
106									-										
107								✓	M	9		2.9	3.2						
108								✓	F	9			3.8						
109				✓				✓	M	8			3.3	✓	✓				
110					✓			✓	M	7									
111								✓	F	8		2.8							
112	✓			✓			✓		F	-	800g								
113								✓	M	9		2.9							
114								✓	F	8			3.4						
115								✓	M	6	800g			✓		✓			
116								✓	M	8	2.4								
117								✓	F	9		3							
118								✓	F	8		2.9							
119								✓	F	8		2.9							

S.No	COMPLICATIONS							NEONATAL OUTCOME									
	Antepartum							Maturity		Sex	Birth Weight			NICU Admission	Discharged	Neonatal death	
Severe Preeclampsia	AP Eclampsia	Placenta Previa	Abruptio	GDM	Hypothyroid	PPH	Preterm	Term	Appar Score	<2.5kg	2.5-3 (kg)	>3kg					
120								✓	M	7	2		✓	✓			
121					✓		✓		M	7			3.2	✓	✓		
122								✓	M	7		2.6					
123								✓	M	8		2.8					
124								✓	F	7			3	✓	✓		
125							✓		F	-	500g						
126								✓	M	8		2.9					
127									-			-					
128								✓	F	7	1.8			✓	✓		
129					✓			✓	M	7			3.3				
130								✓	M	8		2.7					
131								✓	F	6		2.6		✓	✓		
132						✓			F	8		2.5					
133								✓	M	7	2.3						
134									F	-	100g						
135								✓	M	8		2.8					
136								✓	M	8			3.4				
137							✓		F	8	2.1						
138							✓		M	7	1.6			✓	✓		
139								✓	F	8	2.5						
140					✓	✓			M	7			3				
141								✓	M	8		2.8					
142								✓	M	8		2.7					
143									-								
144							✓		M		1.7			✓	✓		
145								✓	F	8		2.9					
146								✓	M	7	2.2			✓	✓		
147								✓	M	8		2.6					
148								✓	M	8		2.8					
149									-								
150	✓						✓		M	5	1.7			✓		✓	

S.No	COMPLICATIONS							NEONATAL OUTCOME									
	Antepartum							Maturity				Birth Weight					
	Severe Preeclampsia	AP Eclampsia	Placenta Previa	Abruptio	GDM	Hypothyroid	PPH	Preterm	Term	Sex	Apgar Score	<2.5kg	2.5-3 (kg)	>3kg	NICU Admission	Discharged	Neonatal death
151								✓	M	8		2.8					
152					✓	✓		✓	F	8			3				
153								✓	M	7		2.8					
154								✓	M	8		2.8					
155								✓	F	9			3.3				
156								✓	F	8		2.7					
157									F	-	600g						
158								✓	M	8		2.9					
159								✓	M	8		2.5					
160		✓					✓		F	6	1.8			✓	✓		
161								✓	M	8		2.9					
162								✓	M	9			3.2				
163									-								
164								✓	M	7	2.4			✓	✓		
165								✓	F	7		2.5		✓	✓		
166								✓	M	7		2.8		✓	✓		
167								✓	F	8		2.9					
168								✓	F	7			3.5	✓	✓		
169								✓	M	8	2.3						
170								✓	M	7	2.4			✓	✓		
171									-								
172						✓		✓	M	8		2.8					
173									F		300g						
174								✓	M	8	2.4						
175			✓				✓		M	7	1.9			✓	✓		
176								✓	F	8		2.9					
177	✓							✓	M	6	2.2			✓	✓		
178								✓	M	8	2.5						

S.No	COMPLICATIONS							NEONATAL OUTCOME									
	Antepartum							Maturity			Birth Weight			NICU Admission	Discharged	Neonatal death	
								Severe Preeclampsia	AP Eclampsia	Placenta Previa	Abruptio	GDM	Hypothyroid				PPH
179								✓		M	8	2.3					
180									✓	F	8		2.7				
181				✓				✓		F	6	2					
182									✓	M	8		2.6		✓	✓	
183									✓	F	8			3			
184									✓	M	8	2.8					
185									✓	M	7		2.6				
186									✓	F	8		2.7				
187									✓	M	8		2.9				
188									✓	F	8		2.7				
189									✓	M	7		2.6		✓	✓	
190									✓	F	8			3			
191								✓		M	7	2			✓	✓	
192									✓	M				3.2			
193									✓	F			2.7				
194									✓	M			2.8				
195									✓	F			2.6				
196								✓		M	8	2.4					
197									✓	F				3.1			
198					✓				✓	M			2.5				
199										F			2.7				
200						✓		✓		M	7	1.9			✓	✓	